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ABSTRACT 
SUSHMITA JHA: Role of NLRs in neuroinflammation, demyelination and 
remyelination in the CNS                                                                              
(Under the direction of Dr Jenny P-Y Ting) 
Sterile inflammation in the brain is recognized as a key component of many neurological 
diseases including multiple sclerosis (MS), amyotrophic lateral sclerosis, Parkinson’s 
disease, and Alzheimer’s disease. An understanding of the mechanisms by which 
neuroinflammation occurs and the molecular mediators involved in this process is necessary 
for identification of potential therapeutic targets. The NLR gene family members have 
emerged as important regulators of immunity and inflammation due to their genetic linkage 
to several human immunologic diseases. In this study, our goal was to ascertain the role of 
NLR dependent cellular pathways in neuroinflammation, demyelination and remyelination. 
An in vivo cuprizone-induced mouse model of demyelination and remyelination along with 
ex vivo primary cell culture assays were utilized.  Mice deficient in NLRP3 (Nlrp3
-/-
), IL-1ȕ
(IL-1ȕ-/-), caspase-1 (casp1-/-), P2X7R (P2X7R-/-), IL-18 (IL-18-/-) and NLRC4 (Nlrc4-/-) were 
used for these studies. 
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1.1 ABSTRACT 
The nucleotide-binding, leucine rich repeat (NLR) proteins are a recently discovered 
family of intracellular pathogen and danger signal sensors. NLRs have emerged as important 
contributors to innate immunity in animals. Although the physiological relevance of these 
genes remains elusive, gene mutations in some of the family members leads to several 
autoinflammatory diseases. The association of mutations in NLR genes to autoinflammatory 
diseases indicates an important function of these genes in inflammation in vivo. This chapter 
reviews the NLR gene family, the NLR inflammasomes, role of inflammasome forming NLR 
proteins in inflammatory diseases and the possible use of some of these NLRs as 
pharmacological targets.   
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1.2 THE NLR GENE FAMILY 
The nucleotide-binding, leucine rich repeat (NLR) gene family is an evolutionarily 
conserved family of genes, important for immune function in animals  (1). There are more 
than 20 NLR genes in humans.  
The NLR gene family members were discovered by their structural similarity to the 
MHC class II gene master regulator, the class II transactivator (CIITA) (2). NLR genes 
encode cytoplasmic proteins with a tripartite domain structure that is conserved with a 
subclass of plant disease resistance genes. This tripartite structure consists of a variable N 
terminal effector domain, a central nucleotide binding domain (NBD) and a variable number 
of C terminal leucine rich repeats (LRRs). Figure 1.1 provides the domain organization of 
some of the NLRs.  
FIGURE 1.1 Domain Organization of NLRs.
NLR proteins have a conserved tripartite structure consisting of an N-terminal effector domain, a central 
nucleotide binding domain (NBD) and a variable number of C-terminal leucine rich repeats (LRRs). The 
following abbreviations have been used here: PYR, pyrin domain; CARD, caspase activating and recruitment 
domain; BIR, baculovirus inhibitor of apoptosis repeat; TE, transcription enhancer and FIIND, function to find 
domain.   
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The NLRs are responsible for rapid sensing of pathogen-associated molecular 
patterns (PAMPs) such as bacterial cell wall components; lipopolysaccaride (LPS), 
lipoproteins and flagellin (3-7), and bacterial and viral nucleic acids(3, 8). In addition, NLRs 
also sense danger associated molecular patterns (DAMPs) such as ATP (9), uric acid (10, 
11), amyloid -ȕ (12), hyaluronan and heparan sulfate (13). Recognition of PAMPs and 
DAMPs by NLR proteins can result in assembly of a caspase-1 activating multi-protein 
complex referred to as the “inflammasome” (14). This is similar to the cytoplasmic multi-
protein complexes assembled for activation of caspase-9 and caspase-8 referred to as the 
apoptosome (containing Apaf-1) and the death-inducing signaling complex (Fas/CD95-
DISC) respectively (15-17). The protein components of the caspase activating platforms are 
present as inactive monomers that oligomerize on exposure to the activating PAMP or 
DAMP signal. Inflammasome formation results in cleavage of caspase-1 from its inactive pro 
protein form to its active mature form. This active caspase-1 then processes the cleavage of 
pro-IL-1ȕ and pro-IL-18 to IL-1ȕ and IL-18, respectively. While IL-1ȕ and IL-18 are the 
most widely studied targets of caspase-1 two recent studies have identified more than 70 new 
targets of caspase-1 ranging from chaperones, cytoskeletal and translation machinery, 
glycolysis and immune proteins (18, 19).  Both IL-1ȕ and IL-18 are proinflammatory 
cytokines.  Release of proinflammatory cytokines and chemokines recruits immune cells 
(such as macrophages/microglia, B cells and T cells) to the site of infection or injury leading 
to phagocytosis of the pathogen or  removal of danger signal, release of antimicrobial 
compounds and inflammation, resulting in resolution of infection and/or cell death. The three 
well known inflammasomes, the NLRP1, NLRP3 and NLRC4 inflammasome complexes and 
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their key component proteins will be discussed in some detail here. Figure 1.2 depicts the 
triggering PAMPs and DAMPs and key component proteins of the four inflammasomes 
discussed here. 
1.3 THE NLR INFLAMMASOMES 
The NLRP3 inflammasome: One of the NLR genes, NLR family, Pyrin-domain 
containing 3 (NLRP3, also Cryopyrin, Nalp3, PYPAF1, CIAS1) is critical for processing of 
caspase-1 and consequently the proinflammatory cytokines interleukin-1beta (IL-1ȕ) and 
interleukin-18 (IL-18) from their inactive pro- forms to their mature active form (20). In the 
presence of bacterial products such as bacterial RNA (8, 21), certain toxins such as; nigericin 
(Streptomyces hygroscopicus) and maitotoxin (marine dinoflagellates), cellular danger 
signals such as ATP (9), uric acid crystals (10), hyaluronan and heparan sulfate (13, 22) and 
amyloid- ȕ (12), environmental danger signals such as  asbestos and silica (23, 24) and alum 
and its adjuvants (23, 25) NLRP3 forms a multi-protein complex with the adaptor protein 
apoptosis-associated speck-like protein containing a CARD (ASC) (20) and pro-caspase-1 
referred to as the NLRP3 inflammasome. Association of NLRP3 with ASC is required for 
recruitment of pro-caspase-1 (26).  The CARD domain of ASC is utilized to recruit pro-
caspase-1by CARD-CARD interactions, thus leading to processing of pro-caspase1 to active 
caspase-1. Caspase-1 is in turn critical for processing and release of IL-1ȕ and IL-18 (27).
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FIGURE 1.2 The NLR Inflammasomes.
In response to pathogen-associated molecular patterns (PAMPs) or damage-associated molecular 
patterns (DAMPs) the NLRs are activated to form multi-protein caspase activating platforms referred to as 
inflammasomes. The NLRP1 inflammasome when activated by muramyl dipeptide or anthrax lethal toxin can 
recruit pro-caspase-1 via direct CARD-CARD interactions and cause its autocatalytic cleavage to mature 
caspase-1. The activated caspase-1 can then process IL-1ȕ and IL-18 from their inactive pro-protein to mature 
active forms. The NLRP3 inflammasome is activated in response to several PAMPs and DAMPs including but 
not restricted to nucleic acids (8, 21, 28, 29), LPS (8), lipooligosaccharide (30), muramyl dipeptide (31), ATP 
(9), uric acid crystals (10), hyaluronan and heparan sulfate (22) and amyloid-ȕ (12), asbestos and silica (23, 24). 
NLRP3 forms a multi-protein inflammasome complex with the adaptor protein apoptosis-associated speck-like 
protein containing a CARD (ASC) and pro-caspase-1. Association of NLRP3 with ASC is required for 
recruitment of pro-caspase-1. The CARD domain of ASC is utilized to recruit pro-caspase-1 by CARD-CARD 
interactions, thus leading to processing of pro-caspase-1 to active caspase-1. Caspase-1 is in turn critical for 
processing and release of IL-1ȕ and IL-18. The NLRC4 inflammasome is a cytosolic sensor of flagellin and 
pathogens such as Salmonella typhimurium, Shigella flexneri and Legionella pneumophila (3-7, 26, 32).
NLRC4 forms a homo-oligomeric inflammasome with caspase-1.  The C-terminal 35 amino acid fragment of 
flagellin is sensed by NAIP5 leading to a NAIP5 dependent cell death while full length flagellin induces NAIP5 
independent but NLRC4 dependent cell death and IL-1ȕ release (33).  
The NLRP1 inflammasome: The human NLR family, Pyrin-domain containing 1
(NLRP1, also NALP1, CARD7, DEFCAP, CLR17.1) inflammasome was the first caspase-1 
activating inflammasome to be identified (34). There is only 1 NLRP1 gene in humans in 
contrast to 3 paralogs in mice; Nlrp1a, Nlrp1b, Nlrp1c (35). The NLRP1 protein in humans 
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consists of an N terminal pyrin domain, central; NBD, NBD associated domain (NAD), LRR, 
and function to find (FIIND) domains, and a C terminal CARD domain. The mouse 
counterparts vary in structure from the human protein; Nlrp1a lacks the N terminal pyrin 
domain, Nlrp1b lacks both the pyrin and NAD domains and Nlrp1c lacks all but the NBD 
and LRR domains. Initial studies on NLRP1 using cell extracts suggested that the NLRP1 
inflammasome in humans consisted of NLRP1, caspase-1, caspase-5 (not present in mice) 
and ASC (36, 37). Further studies revealed that even though the presence of ASC is not 
required for processing of caspase-1 by the NLRP1 inflammasome it does augment this 
function (38). The mouse Nlrp1b inflammasome is activated in response to Bacillus 
anthracis (39) and this activation is attributable to the anthrax lethal toxin. Faustin et al.
utilized a cell-free system with recombinant NLRP1 inflammasome components to show a 
two step mechanism of inflammasome assembly and caspase-1 activation in response to the 
peptidoglycan component muramyl dipeptide (MDP) (38). Subsequently, Hsu et al. showed 
that MDP stimulation of macrophages leads to association of NLRP1 with NOD2 (39). Gel 
filtration experiments revealed a complex consisting of NLRP1, NOD2 and caspase-1.  
Moreover, Bacillus anthracis infection also induces NOD2 and caspase-1 dependent IL-1ȕ
secretion. These results suggest the existence of a NLRP1 and NOD2 containing 
inflammasome, and the potential for MDP to activate both NLRP1 and NOD2.  However 
there is no data to show that MDP binds to either NLRP1 or NOD2, thus how MDP activates 
this pathway is unclear.
The NLRC4 inflammasome: NLR family, Caspase Recruitment domain containing 
4 (NLRC4, also IPAF, CLAN, CARD12) is a cytosolic sensor of flagellin and flagellated 
pathogens such as Salmonella typhimurium (5, 26) and Legionella pneumophila (3) and non-
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flagellated pathogens such as Shigella flexneri (7) and Pseudomonas aeruginosa (32).
NLRC4 forms a homo-oligomeric inflammasome with caspase-1 (26). NLRC4 was shown to 
be highly expressed in human brain, bone marrow and the human monocytic cell line THP-1 
by RT-PCR (40). Initial characterization of NLRC4 in human tissues and cell lines 
demonstrated its direct association with the CARD domain of procaspase-1 through CARD-
CARD interactions (40, 41). This interaction can cause autocatalytic processing of 
procaspase-1 to Caspase-1 (40). A constitutively active NLRC4 could cause autocatalytic 
processing of procaspase-1 leading to caspase-1 dependent apoptosis in transfected cells (40). 
In macrophages, activation of the NLRC4 inflammasome by cytoplasmic flagellin leads to 
caspase-1 activation and IL-1ȕ release (4, 5, 26).  NLRC4 can interact directly with 
procaspase-1 through CARD-CARD interaction, however direct interaction of ASC with 
NLRC4 has not been demonstrated.  Nonetheless, ASC-deficient macrophages show 
defective caspase-1 activation and IL-1ȕ release in response to Salmonella, Shigella and 
Pseudomonas infection indicating that the function of NLRC4 is ASC-dependent (7, 26, 32).
The NAIP5 inflammasome:  NLR apoptosis-inhibitory protein 5 (NAIP5 also 
BIRC1, NLRB1) is also a cytosolic sensor of flagellin. While the human genome has one 
Naip5 gene, there are 7 paralogs of NAIP, Naip1-7, in mice (42). Based on co-
immunoprecipitation studies utilizing over-expressed Myc-tagged NAIP and HA- tagged 
NLRC4 in HEK293 cells, these two proteins can co-associate, suggesting that they can be 
part of the same caspase-1 activating inflammasome (43). Recently, Lightfield et al. reported 
a novel role of NAIP5 in inflammasome activation in response to the C-terminus of flagellin 
and Legionella pneumophila infection (33). Interestingly, while transduction of macrophages 
with a C-terminal 35 amino acid fragment of flagellin led to NAIP5-dependent cell death, 
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full length flagellin induced NAIP5 independent but NLRC4 dependent cell death and IL-1ȕ
release. Moreover, since NLRC4 can sense some non-flagellated bacteria (7, 32) this might 
point to a mechanism for differential sensing of bacteria via regulation of inflammasome 
components. However, NAIP5 has no caspase domain, and it needs NLRC4 to activate pro-
caspase 1.  Thus NAIP5 appears to possess NLRC4 dependent and independent functions. 
1.4 THE NLR INFLAMMASOME END PRODUCTS
Caspase-1, IL-1ȕ and IL-18:  Activation of the NLRP1, NLRP3 and NLRC4 
inflammasomes leads to processing of inactive pro-caspase-1 to active caspase-1. Caspase-1 
is an inflammatory caspase whose activation by the inflammasomes leads to its processing of 
the proinflammatory cytokines IL-1ȕ and IL-18. Caspase-1 levels are significantly increased 
in peripheral blood mononuclear cells from MS patients (44). Moreover, caspase-1 is known 
to contribute to the pathology of EAE (45, 46).
IL-1ȕ (Interleukin-1ȕ) is a 17kDa proinflammatory cytokine that is essential for 
innate immune responses. IL-1ȕ is released primarily by microglia and macrophages in the 
central nervous system (CNS). IL-1ȕ promotes leukocyte infiltration by inducing expression 
of many cytokines, chemokines and adhesion molecules. The release of IL-1ȕ also mobilizes 
neutrophils and other immune cells to help resolve infections and promote wound healing. 
Chronic release of IL-1ȕ however, can be detrimental and cause skin rashes, inflammatory 
arthritis, and systemic fever. It is for this reason that IL-1ȕ production is very tightly 
regulated at the levels of transcription, translation and release. IL-1ȕ is produced as an 
inactive precursor that has to be cleaved by caspase-1 to generate the mature active form.  
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IL-18 (Interleukin-18) is an 18kDa member of the IL-1 family of cytokines. IL-18 is 
produced by several immune and non-immune cells including monocytes, macrophages, 
splenocytes, keratinocytes, microglia, macrophages and astrocytes (47-49). In the CNS, IL-
18 induces microglial production of proinflammatory cytokines such as IL-1ȕ, TNFĮ and 
matrix metalloproteinases (MMPs). Extravasation of polymorphonuclear leukocytes (PMNs) 
and monocytes/macrophages is amplified by IL-18 dependent upregulation of intercellular 
adhesion molecule-1 (ICAM-1) on endothelial cells. 
1 .5 INFLAMMASOME NLRS AND INFLAMMATORY DISEASE:  
It has been recently proposed that NLR related inflammatory diseases can be 
classified into 3 categories based on mutations of core components of the inflammasome 
complexes (intrinsic inflammasomopathies), accessory or regulatory proteins upstream or 
downstream of the inflammasome complex (extrinsic inflammasomopathies) and disease 
resulting from aberrant activation of the inflammasome complex (acquired or complex 
inflammasomopathies) (50, 51). Table 1.2 provides a list of the disease associated mutations 
discussed in this section. 
Intrinsic inflammasomopathies: 
Cryopyrin-associated Periodic Syndromes (CAPS or cryopyrinpathies)- Autosomal 
dominant mutations in NLRP3 in humans leads to three autoinflammatory syndromes 
collectively referred to as Cryopyrin-associated Periodic Syndromes (CAPS or 
cryopyrinpathies) (52, 53 , 54-56). Gain of function mutations of NLRP3, cause a lowered 
activation threshold which leads to IL-1ȕ secretion even in the absence of a stimulus in vitro
(34, 57). All CAPS are characterized by increased levels of IL-1ȕ in the absence of infection.
CAPS consist of a spectrum of diseases ranging from the mild such as Familial Cold
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Autoinflammatory Syndrome (FCAS), to the intermediate such as Muckle Wells Syndrome 
(MWS) and the severe such as Chronic Infantile Neurological, Cutaneous and Articular 
syndrome (CINCA) also known as Neonatal-Onset Multisystem Inflammatory Disease
(NOMID). All three syndromes present with fever, urticaria-like rash and varying degrees of 
arthropathy and neurological manifestations (1, 58-60). Of the 3 CAPS, FCAS consists of the 
mildest symptoms including cold-induced urticaria and mild arthralgia.  MWS is 
intermediate with spontaneous urticaria (not cold-induced), sensorineural hearing loss, 
arthralgia and in some cases renal amyloidosis. CINCA is the most severe with spontaneous 
urticaria, deforming arthropathy, sensorineural hearing loss, and chronic aseptic meningitis. 
 In 2001 Hoffman et al, sequenced regions of chromosome 1q44, this region was 
known to contain mutations that lead to FCAS and MWS (61). This screening approach led 
to the discovery of 4 distinct mutations in exon 3 of a 9 exon gene that segregated with the 
disorder in 3 families with FCAS and 1 family with MWS. This gene is now referred to as 
NLRP3. NLRP3 is a cytoplasmic protein that is expressed in monocytes, macrophages, 
granulocytes, dendritic cells, non-keratinized epithelial cells, osteoblasts, uroepithelial cells, 
and T and B cells (62, 63). NLRP3 is composed of 3 distinct domains the N terminal pyrin 
domain (PYD), the central nucleotide binding domain (NBD), and the C terminal leucine- 
rich repeats (LRRs). All 84 of the disease associated mutations lie within exon 3 which 
encodes the central NBD of NLRP3 (64). The PYD of NLRP3 is essential for homotypic 
interactions with PYD domain of other proteins. The NBD is thought to be involved in 
oligomerization of NLRP3 to form the inflammasome complex. The LRR domain is 
suggested to mediate interaction with intracellular or extracellular PAMPs or DAMPs albeit 
no evidence has been reported.   Several studies reported the role of NLRP3 in response to 
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bacterial RNA, dsRNA, viral RNA, uric acid crystals, TLR ligands and ATP in Nlrp3-
deficient mice (8-10, 20, 21). Recently, the Strober and Hoffman labs separately generated 
mice expressing mutations corresponding to human FCAS or MWS mutations (65, 66). 
Meng et al. generated a mouse expressing the R258W mutation corresponding to the human 
R260W substitution (66). Brydges et al. generated two lines of mice carrying the A350V and 
L351P mutations corresponding to the human A352V and L353P mutations downstream of a 
LoxP –flanked Neomycin resistance cassette in reverse orientation (65). When these mice 
were crossed with Cre recombinase expressing mice they would express the mutated NLRP3 
protein in all tissues (CreZ), in myeloid cells only (CreL), or after exposure to tamoxifen 
(CreT).  The mice generated by both studies developed severe cutaneous lesions associated 
with inflammatory cell infiltrates, recapitulating some of the urticaria-like skin lesions in 
MWS patients. Interestingly, both studies could recapitulate human disease by either 
expressing mutant NLRP3 only in myeloid cells (65) or by generation of bone marrow 
chimeras with the mutant R258W protein in bone marrow cells (66). Moreover, both groups 
found that the disease phenotype was only partially dependent on IL-1ȕ and was dependent 
on the expression of mutated NLRP3 in antigen presenting cells and not in T cells.
Vitiligo – This is an autoimmune disease resulting from destruction of melanocytes 
causing patches of depigmented skin in patients. Vitiligo patients are at a higher risk for 
development of other autoimmune diseases such as rheumatoid arthritis, diabetes, lupus and 
thyroid disease.  Fine scale association analyses of patients with vitiligo identified Nlrp1
variants that are associated with development of vitiligo alone (67). The mechanism by 
which NLRP1 leads to skin hypopigmentation in vitiligo remains unknown.  
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NLR Mutation(s) 
(Amino acid change) 
Disease 
association 
Reference 
NLRP3 A439V, V198M, E627G, A352V FCAS and MWS (61) 
R260W, D303N, T348M, A439T, and G569R FCAS and MWS (58) 
F575S, Q306L, T436N, H358R, M662T, D303N, 
F309S
CINCA (62) 
L264H, D303N, A374N, Y570C, F523L CINCA (59) 
L353P FCAS (60) 
T348M, E354D, L632N,R260L, R260P, D303N, 
D303G, F309S, T405P, T436I, Y570C 
CINCA (56) 
NLRP1 L155H Vitiligo (67) 
NLRP12 R284X,  V635T Guadeloupe 
Variant Periodic 
Fever Syndrome 
(68) 
TABLE 1.1 Disease associated mutations in inflammasome forming NLRs  
Extrinsic inflammasomopathies: 
Extrinsic inflammasomopathies are diseases arising from defects in NLR proteins that are not 
part of an inflammasome complex or from defects in NLR protein associated proteins.
Familial Mediterranean fever (FMF) - FMF is one of the most common 
autoinflammatory diseases. It affects individuals of Mediterranean ancestry and the carrier 
rates can be as high as 1 in 3 (69).  FMF is characterized by acute attacks of fever and 
inflammation of the joints (arthritis), skin (pustular skin disease), pleura (pleuritis) or 
peritoneum (peritonitis) (70). These episodes may last 12-72 hours to days. FMF is clinically 
divided into 2 sub types: type 1 is characterized by short episodes of peritonitis, synovitis, 
pleuritis, pericarditis and meningitis while type 2 is characterized by amyloidosis. Before the 
development of therapy, amyloidosis frequently led to renal failure by age 40. 
   Segregation analyses of families manifesting FMF symptoms led to the discovery 
that FMF is a single-gene recessive disorder with incomplete penetrance (51). Further 
linkage studies established the FMF susceptibility locus to the short arm of chromosome 16. 
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All genes within the 200-kb region were screened for disease associated mutations which led 
to the discovery of the Mediterranean fever (MEFV) gene. MEFV consists of 10 exons 
covering 15kb of DNA which encodes a 781 amino acid protein called pyrin.  
Pyrin is expressed in peritoneal and synovial fibroblasts, granulocytes, dendritic cells 
and monocytes (71, 72).  Pyrin is composed of four domains: the N terminal pyrin domain 
and 3 C terminal domains including- a B box zinc finger domain (B-box), an Į helical coiled 
coil domain (CC) and a B30.2 (PRYSRPY) domain. The B-box domain is necessary and 
sufficient for interactions with the proline serine threonine phosphatase interacting protein 
(PSTPIP1) (73). The B-box can also act as an intramolecular inhibitor by binding to the PYD 
domain and thus inhibiting pyrin interactions with ASC which occur via PYD-PYD 
interactions (74). The CC domain is required for homotrimer formation during the ASC 
pyroptosome formation (74).   The B30.2 domain plays a role in interaction with the NBD of 
NLRP3 (75). Pyrin can also bind to caspase-1 via its B30.2 domain thus reducing caspase-1 
activation (75, 76).
Mice expressing a truncated form of pyrin produce increased amounts of caspase-1 
and IL-1ȕ in response to stimuli such as a LPS and IL-4 (77). Most mutations associated with 
FMF in humans affect the B30.2 domain however; the contributions of these to the clinical 
disease remain uncertain (75).     
Recent studies utilizing the human monocytic cell line, THP1, have suggested that 
PSTPIP1 interaction with pyrin can induce pyrin interaction with ASC leading to formation 
of a pyroptosome complex which can cause procaspase-1 cleavage to active caspase-1 (74, 
78).
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Crohn’s disease and Ulcerative colitis- Crohn’s disease (CD) and ulcerative colitis 
(UC) are collectively referred to as inflammatory bowel disease (IBD). IBD constitutes 
chronic disease of the gastrointestinal tract with unknown etiology. The prevalence of UC 
and CD are between 150-200 per 100,000 in western countries (79).  Though the etiology 
remains unknown both genetic predisposition and intestinal microflora are known to 
contribute to the pathology.
UC is characterized primarily by pathology of the colon, though the rectum is 
involved in 95% of the patients. Inflammation is limited to the mucosa and consists of 
continuous but variable severity of ulceration, edema and hemorrhage along the length of the 
colon. Acute and chronic inflammation is characterized by infiltration of PMNs and 
mononuclear cells, crypt abscesses, distortion of the mucosal glands and goblet cell 
depletion.
In contrast to UC, CD can affect any part of the gastrointestinal tract from the 
oropharynx to the perianal area. The common locations in decreasing order are the ileocecal 
region, followed by the terminal ileum, diffuse small bowel and colon. The pathology 
consists of small superficial ulcers over a Peyer’s patch and focal chronic inflammation that 
can extend to the submucosa and can lead to granuloma formation.  
Even though, mononuclear cells from the lamina propria of UC and CD patients show 
enhanced TNF, IL-6 and IL-1 secretion (80), no NLR gene has been implicated in the 
pathology of UC yet.  Inheritance of CD was known to be linked to chromosome 16. Using 
linkage and genetic association analyses two groups simultaneously discovered that 
mutations in NOD2 gene showed strongest linkage to CD (81, 82).
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NOD2 is expressed primarily by myeloid lineage cells. The NOD2 protein has two N-
terminal CARD domains , a central NBD domain and 10 C terminal LRRs. NOD2 interacts 
with RICK/RIP2, via CARD-CARD interactions, to activate the NF-țȕ and mitogen-
activated protein (MAP) kinase signaling pathways (83-86). The NBD domain has ATP-
binding activity and the LRRs mediate intracellular recognition of bacterial cell wall 
component MDP by an unknown mechanism (87).  While most CD mutations are found in 
the NOD2 gene, three mutations in the C-terminal account for 80% of the NOD2 associated 
CD patients.
The mechanisms by which CD mutations lead to inflammatory bowel disease remain 
largely unknown. Thus far, the results obtained from animal studies vary with the cell types 
under study. BMDMs from mice with a CD associated NOD2 mutation exhibit increased NF-
țȕ activity and IL-1ȕ in response to MDP (86). This is consistent with increased NF-țȕ
activation in lamina propria of CD patients (88) however, PBMCs from these patients show 
decreased activation in response to MDP (89, 90).  Another study utilizing MDP activation of 
NOD2 showed a down regulation of multiple TLR induced responses (91). This may provide 
a possible mechanism for increased susceptibility to intestinal inflammation following 
exposure to gut microflora.  
NOD2 is not the only gene involved in innate immunity that is also involved with 
CD. More than 30 genetic disease susceptibility factors associated with CD have been 
identified in humans such as several autophagy related genes such as ATG16L1 and Irgm.
Mice deficient in Atg16L1 exhibit abnormalities in granule exocytosis from their Paneth 
cells, similar to that seen in CD patients (92). Moreover these mice are also more susceptible 
to chemical-induced colitis in an IL-1ȕ dependent manner (93).  Irgm deficient mice have a 
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defective capacity to clear intracellular pathogens (94, 95). These findings suggest a complex 
interplay between NOD2, autophagy genes and other immunity genes that could affect 
susceptibility to CD.
Blau syndrome- Blau syndrome is characterized by granulomatous uveitis, arthritis, 
and skin rashes with camptodactyly (flexion contractures of the fingers and toes) (96). Blau 
syndrome is caused by mutations in the NOD2 gene. In contrast to CD mutations that target 
the LRR, in Blau syndrome the mutations target the NBD of NOD2.  
Pyogenic Arthritis Pyoderma Gangrenosum and Acne syndrome (PAPA) – Patients
with PAPA syndrome manifest episodic destructive arthritis that may lead to periosteal 
proliferation and ankylosis. Skin manifestations range from severe cystic acne on the face, 
chest or back to pyoderma gangrenosum, an ulcerating skin condition that can be triggered 
by minor trauma. Linkage studies in patients with PAPA lead to chromosome 15q (97). 
Further studies lead to the discovery of two mutations within the gene encoding PSTPIP1.
PSTPIP1 is expressed in hematopoietic tissues including spleen and peripheral blood 
leukocytes (73). The PSTPIP1 protein contains a CIP4 domain, CC domain and a SH3 
domain. The CC and SH3 domains are utilized for interaction with the B-box domain of 
pyrin (73). Mutations in PSTPIP1 lead to its hyperphosphorylation which increases its 
avidity for pyrin (73, 74). Cell lines co-transfected with PAPA-associated PSTPIP1 mutants 
and pyrin show increased IL-1ȕ production (73).
Complex or acquired inflammasomopathies: 
Complex or acquired inflammasomopathies arise from aberrant inflammasome activation by 
environmental or endogenous stimuli. 
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Gout/ Pseudogout – Gout and pseudogout are rheumatic diseases caused by 
deposition of monosodium urate (MSU) and calcium pyrophosphate dihydrate (CPPD) 
crystals respectively, in joints and periarticular tissues.  This deposition can lead to acute or 
chronic inflammation of the joints. MSU and CPPD crystals increase caspase-1 activation 
and IL-1ȕ release from murine macrophages in an NLRP3 and ASC dependent manner (10). 
The importance of IL-1ȕ in gout studied in mice was further supported by the resistance of 
mice deficient in the IL-1 and TLR signaling adaptor protein MyD88 to MSU induced 
inflammation (98).  While TLR deficient mice still showed inflammation, the IL-1ȕ receptor 
deficient mice did not thus indicating a specific role for IL-1 signaling in the pathology. 
Finally, bone marrow reconstitution experiments established that IL-1 receptor expression in 
non-hematopoietic cells and hematopoietic cells is required for initiation of inflammation 
upon MSU stimulation indicating IL-1ȕ engagement to its receptor in this model.  
Alzheimer’s disease- Alzheimer’s disease (AD) is a neurodegenerative disease that 
affects more than 20 million individuals worldwide and approximately 4.5 million Americans 
(99). Amyloid-ȕ oligomers lead to the pathogenic lesions in AD.  Amyloid-ȕ oligomers and 
fibrils have been shown to signal via the TLRs leading to inflammatory responses (100). 
However, TLR signaling can also be neuroprotective since it aids in recruitment of T cells 
and enhances phagocytosis and clearance of amyloid ȕ by microglia (101). NLR 
inflammasomes are known to trigger release of IL-1ȕ and IL-18. These cytokines are 
upregulated in both brain and plasma of patients with AD (102-104). Amyloid ȕ oligomers 
are known to be more potent inducers of IL-1ȕ release than fibrillar amyloid ȕ. Moreover, 
transgenic Alzheimer’s mice express increased IL-1ȕ staining in reactive astrocytes that 
surround the amyloid ȕ plaques. Human brain autopsy studies from AD patients show 
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increased release of IL-1ȕ from microglia in AD brain than normal brain after amyloid ȕ
peptide stimulation (105).   
Halle et al., recently showed that, amyloid ȕ protein when phagocytosed by human 
microglia could activate the Nlrp3 inflammasome and cause IL-1ȕ release (12). Amyloid-ȕ
phagocytosis induces lysosomal destabilization and subsequent release of cathepsin B which 
leads to NLRP3 inflammasome activation. 
Asbestosis and Silicosis- Prolonged inhalation of asbestos and silica lead to two 
environmentally induced forms of pulmonary fibrosis referred to as asbestosis and silicosis 
respectively. Alveolar macrophages from individuals with prolonged exposure to asbestos 
exhibit enhanced IL-1ȕ release (106). Moreover, Nlrp3-deficient mice show decreased IL-1ȕ
release in response to asbestos and silica (23, 24) indicating a role for NLRP3 in the immune 
response to asbestos and silica. Silica crystals once phagocytosed cause lysosomal damage 
leading to release of the lysosomal protease cathepsin B which can activate the cytoplasmic 
NLRP3 inflammasome. Inhibition of phagosomal acidification or cathepsin B impairs 
NLRP3 inflammasome activation (23).  In the bleomycin (BLM)-induced lung injury model 
of fibrosis, the NLRP3 inflammasome is triggered by local uric acid release in response to 
DNA damage and degradation after BLM injury suggesting that uric acid may be one of 
triggering DAMPs in lung fibrosis and disease (107).  
Guadeloupe Variant Periodic Fever Syndrome (FCAS2) - This syndrome was first 
reported in two families in Guadeloupe and thus named Guadeloupe Variant Periodic Fever 
Syndrome (68). Based on the similarities in symptoms to FCAS this syndrome is also 
referred to as FCAS2. Individuals with this syndrome present with cold-induced 
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heterogeneous symptoms including fever, arthralgia, myalgia, sensorineural hearing loss, 
aphthous ulcers and lymphadenopathy.  
Genetic studies in patients with Guadeloupe Variant Periodic Fever Syndrome 
revealed 2 missense mutations, 1 nonsense mutation and 1 deletion mutation, in the Nlrp12
gene. The nonsense mutation caused a truncation within the NBD domain of the protein 
while the splice mutation caused a deletion of the C-terminal LRRs.  NLRP12 was 
recognized as one of the few NLR proteins that can suppress NF-țȕ signaling (108, 109).
Both the missense mutations in Nlrp12 caused a reduction in the suppression of NF-țȕ
signaling by NLRP12, while the NBD mutation caused a more significant impact on normal 
NLRP12 induced NF-țȕ signaling as compared to the LRR mutation.
1. 6 NLRS IN THE BRAIN 
The initial characterization of NLRs lead to the belief that they were expressed in cells that 
contributed to innate immunity such as monocytes, macrophages and dendritic cells. 
However, recent research has confirmed that they are almost ubiquitously expressed 
throughout the human body. Interestingly, different inflammasome components show 
distinct, non-overlapping tissue and cellular distribution suggesting different roles in 
different cell types (110). Even though, the expression of the activating surface receptors 
upstream of the inflammasome (such as TLRs and purinergic receptors such as P2X7R) and 
downstream signaling molecules of inflammasome activation (such as IL-1ȕ, IL-18 and 
caspase-1) is well characterized in the normal and diseased CNS, the expression of NLRs in 
the CNS remains largely uncharacterized. Some NLRs such as, NLRP2 (111), NLRP10 
(112), NLRX1 (113) and NAIP4 (113, 114) have been shown to be expressed in brain tissue 
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by RT-PCR however, their cellular localization remains undetermined. Here we present some 
recently published findings regarding the expression of NLRs in the brain.  A summary of the 
findings is reported in Table1.2. 
Microglia:  
Historically, the CNS was thought to be an immunologically privileged site because it 
lacks lymphatic drainage and is physically separated from the rest of the body by a blood 
brain barrier. However it is well established now that there is an intact immune surveillance 
of the CNS. Microglia are hematopoietic-derived, resident immune cells of the CNS. 
Microglia constitute approximately 10% of the cells in the CNS. During development 
microglia function to structure neuronal architecture while in adults they remain dormant 
until challenged. Once activated microglia perform several functions. They phagocytose 
microbes, apoptotic cells and debris, present antigens to T cells and release several cytokines 
and chemokines including but not restricted to IL-1ȕ, TNF-Į, IL-18 and IL-6.  Several NLRs 
have been reported to be expressed in microglia including the MHC class II transactivator 
(CIITA) (115, 116), NOD2 and NLRP3.  The NLR adaptor protein ASC is also expressed by 
microglia (117). 
Astrocytes:
Astrocytes perform several diverse roles in the CNS. Astrocytes are essential to 
neuronal survival and maintaining the blood brain barrier. They provide nutrients such as 
glucose to neurons and play a key role in the repair and scarring process in the brain. 
Astrocytes have their foot processes in close contact with endothelial cells and therefore 
encounter T cells first. Astrocytes can act as APCs since IL-1 detected in the supernatants of 
cultured astrocytes is capable of T cell activation. Moreover, APCs express MHC class II 
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antigens and astrocytes can be made to express these by the T cell-derived factor IFN-Ȗ.
Similar to microglia, astrocytes express a wide variety of NLRs including the MHC class II 
transactivator (CIITA) (116, 118), NOD1 and NOD2.The adaptor protein ASC is also 
expressed by astrocytes (117).
Neurons:
Even though most NLR proteins are expressed by cells that come in contact with 
antigens such as microglia, macrophages and astrocytes, recent research has shown that 
several NLR family members are expressed in neurons. Kummer et al. showed that NLRP1 
is expressed by pyramidal neurons (110).  Shortly after this discovery, a NLRP1 
inflammasome consisting of NALP1, ASC, caspase-1, caspase-11 (the rodent ortholog of 
human caspase-5) and the X-linked inhibitor of apoptosis protein (XIAP) was shown to be 
present in rat spinal cord motor neurons, utilizing protein co-immunoprecipitation and 
immunofluorescence experiments (117). NAIP1, an NLR involved in inhibition of cell death, 
is known to be predominantly expressed in neurons, macrophages and/or dendritic cells (119-
122).
Mature Oligodendrocytes:
Oligodendrocytes are the myelin-producing cells of the CNS. ODG progenitors give 
rise to mature myelinating oligodendrocytes. Very little is known about the expression of 
NLR proteins in oligodendrocytes or their progenitors. The NLR adaptor protein ASC is 
known to be expressed by mature oligodendrocytes (117). NLRP1 was recently shown to be 
expressed by oligodendrocytes in the mouse cerebral cortex by immunohistochemistry (110). 
These authors also found a nuclear expression of NLRP1 in their study.   
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NLR 
(HUGO 
nomenclature) 
Alternative or 
previous name(s) 
Expression References 
Apaf1 Brain {Yoshida, 1998 #233} 
CIIta MHC2TA, C2TA Microglia, Astrocytes {Stuve, 2002 #238}, 
{O'Keefe, 1999 #237} 
Naip1 Spinal Motor neurons {Holcik, 2000 #232} 
{Pari, 2000 #257} 
Naip4  Brain and Spinal cord 
 (by RT-PCR) 
{Gotz, 2000 #256} 
{Pari, 2000 #257} 
NLRC3 Nod3, CLR16.2 {Conti, 2005 #24} 
NLRC4 IPAF, Card12  Brain  
Cellular localization 
unknown 
{Poyet, 2001 #128} 
NLRP1 NALP1,CARD7, 
DEFCAP,CLR17.1 
Pyramidal neurons, 
oligodendrocytes 
{de Rivero Vaccari, 
2008 #234} 
NLRP10 NALP10,NOD8, 
PYNOD,CLR11.1 
Brain (by RT-PCR) {Wang, 2004 #258} 
NLRP12 Monarch1,PYPAF7,C
LR19.3 
NLRP2 NALP2, 
PYPAF2,CLR19.9 
Brain (by RT-PCR) {Kinoshita, 2005 #235} 
NLRP3 CIAS1, Cryopyrin, 
Pyrin 1,  
Microglia, macrophages 
 (by RT-PCR) 
NLRX1 Nod9, CLR11.3 Brain (by RT-PCR) 
Cellular localization 
unknown 
{Tattoli, 2008 #249} 
NOD1 CARD4, CLR7.1 Astrocytes {Sterka, 2006 #254} 
{Rodriguez-Martinez, 
2005 #251} 
NOD2  Astrocytes, microglia  {Rodriguez-Martinez, 
2005 #251; Chen, 2008 
#252; Guo, 2006 #253; 
Sterka, 2006 #254} 
ASC
(NLR Adaptor 
protein) 
Astrocytes, ODGs, 
microglia 
{de Rivero Vaccari, 
2008 #234} 
   
Table 1.2: Nomenclature and expression of NLR family members in the CNS
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1. 6 ENDOGENOUS INITIATORS OF INFLAMMASOME ACTIVATION IN THE 
BRAIN 
The NLR genes, particularly those associated with the inflammasome function, have 
gained much interest as sensors of pathogen associated molecular patterns (PAMPs) as well 
as damage-associated molecular patterns (DAMPs), however their roles in inflammatory 
disorders of the brain have not been extensively studied. This section lists the known and 
possible endogenous activation stimuli in the brain for the NLRP1, NLRP3 and NLRC4 
inflammasomes. 
ATP and K
+
efflux:
Extracellular ATP availability in the CNS is a balance of release and enzymatic 
degradation. Pathological events such as mechanical or metabolic stress, inflammation, 
cellular injury, or changes in ionic environment can stimulate ATP release leading to 
widespread increase in ATP concentrations that can activate P2X7Rs on microglia and 
astrocytes.  P2X7Rs are ATP gated ion channels that are activated at ATP concentrations of 
1mM whereas other P2X receptors are activated at concentrations of  100µM. P2X7Rs are 
expressed on monocytes, macrophages, microglia, astrocytes, dendritic cells, mast cells and 
lymphocyte populations (123-127). Continuous ligation of P2X7Rs causes their 
transformation into pores as large as 900 Da and consequently to cell death (128). Recent 
research utilizing macrophages from Nlrp3
-/-
 and C57Bl/6 mice has shown that pannexin-1 is 
critical for caspase-1 activation and IL-1ȕ secretion in LPS-stimulated macrophages pulsed 
with ATP (9, 129). The role of P2X7Rs during inflammation in experimental autoimmune 
encephalomyelitis (EAE) remains controversial, one study utilizing the MOG 35-55 model of 
EAE on P2X7R
-/-
mice showed delayed EAE (130) while another study utilizing the same 
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model and bone marrow chimera studies suggested exacerbated EAE in P2X7R
-/-
mice (131) 
and in chimeras transplanted with P2X7R
-/-
mice bone marrow.  
ATP and K
+
 efflux have also been shown to be involved in cerebral injury. 
Intracellular K
+
is known to decrease during hypoxic and ischemic injury. Decrease in 
intracellular K
+
 activates the NLRP3 and NLRP1 but not the NLRC4 inflammasome(s) 
(132). K
+
 efflux is also involved in activation of NLRP1 inflammasome and release of IL-1ȕ
from cultured spinal motor neurons (117).  
Myelin:  
Myelin is a lipid rich membranous insulation of axons in the CNS and PNS that is 
critical for neuronal conduction. The protein content and structure of myelin varies between 
the CNS and PNS (133). Axonal damage, mature oligodendrocyte or Schwann cell death, 
leads to demyelination and accumulation of myelin debris. Clearance of myelin debris by 
macrophages and microglia is central to the repair mechanisms during demyelination in both 
central and peripheral nervous system diseases (134). Removal of myelin debris is critical for 
resolution of inflammation, further death of oligodendrocytes and differentiation of ODG 
progenitors for remyelination (135).  Myelin phagocytosis is an important feature of EAE as 
well as autoimmune diseases such as multiple sclerosis. Both CNS and PNS myelin proteins 
can cause murine macrophages to release proinflammatory cytokines such as TNF-Į, IL-12, 
and angiotensin converting enzyme (ACE) (136). Proinflammatory cytokines, such as TNF- 
Į and IL-1ȕ are known to induce mature oligodendrocyte death in vitro and in vivo leading to 
a vicious cycle of neuroinflammation. Myelin basic protein (MBP) is a protein common to 
both CNS and PNS myelin. Treatment of cultured oligodendrocytes with exogenous MBP 
causes a rapid and dose dependent death caused by rapid and sustained increase in 
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intracellular calcium (137). However, treatment of cultured oligodendrocytes with MBP 
peptides does not lead to their death, suggesting that the degradation of MBP during 
demyelination may prevent further cell death (137). Myelin debris can activate the 
complement system to form membrane attack complexes that disintegrate intact myelin (138, 
139). Moreover, myelin debris impairs remyelination in the adult rat CNS by inhibiting 
oligodendrocyte precursor cell differentiation (135, 140). There are several receptor 
complexes that are involved in myelin phagocytosis including scavenger receptors I and II 
(SR-A I/II), complement receptor 3 (CR-3), Galectin-3 and the Fc gamma receptor (FcȖR)
(141-145).  It is possible that following myelin phagocytosis the NLRP3 inflammasome is 
activated and results in modulating phagocytosis by affecting expression or signal 
transduction of some of the receptors required for myelin phagocytosis.   
1. 7 NLRS IN NEUROINFLAMMATION 
Neuroinflammation is a key component of many neurological diseases including 
multiple sclerosis (MS), amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s 
disease (AD). An understanding of the mechanisms by which neuroinflammation occurs, and 
the molecular mediators involved in this process, is necessary for identification of potential 
therapeutic targets.
Role of NLRs in multiple sclerosis (MS): MS is an inflammatory neurodegenerative 
disease, that affects more than 2.5 million individuals worldwide (146). The severely 
debilitating symptoms of MS, including sensory and motor dysfunctions, and reduced 
cognitive function, result from demyelination and neuroinflammation of the central nervous 
system (CNS) (147-152). There are three different categories of experimental CNS 
demyelination- i) Toxin-induced (cuprizone, ethidium bromide and lysolecithin, ii) 
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autoimmune-induced (experimental autoimmune encephalomyelitis (EAE) and iii) virus-
induced (theiler’s murine encephalomyelitis virus (TMEV), Semliki forest virus (SFV)). The 
cuprizone induced and the EAE models will be discussed in detail here since this forms the 
basis of my thesis project. 
A. The cuprizone model of CNS demyelination and remyelination Copper
is an essential trace element that is required for a number of enzymes involved in the 
electron transport chain (cytochrome oxidase), skin and hair pigmentation 
(Tyrosinase), skeletal development (ascorbate oxidase), elastin and collagen cross 
linking (lysyl oxidase), and breakdown of dopamine, norepinephrine and epinephrine 
(monoamine oxidase). Inability to absorb copper in the hereditary disease, Menkes 
kinky hair syndrome, leads to skin, hair and connective tissue disturbances and 
progressive neurological deficits leading to lethality by age 3 (153, 154). Cuprizone 
(bis-cyclohexanone-oxaldihydrazone) is a copper chelator that when fed in the diet 
leads to copper deficiency and predictable CNS demyelination. Oligodendrocytes are 
particularly sensitive to low concentrations of cuprizone that leaves other cells 
unaffected (155, 156). The mechanism of cuprizone-induced demyelination remains 
unknown however, it has been hypothesized that cuprizone-induced disturbance in 
mitochondrial function and energy metabolism in oligodendrocytes leads to 
demyelination (156). Cuprizone causes disruption in formation of myelin by causing 
a reduction in myelin basic protein (MBP) and myelin-associated glycoproteins 
(MAG) (157).
Dr. Glenn K. Matsushima established the cuprizone-induced model of 
demyelination and remyelination in the C57Bl/6 strain to take advantage of the many 
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transgenic and knockout mice available on this genetic background. In this model 
mice are fed ground chow containing 0.2% cuprizone ad libidum for 6 weeks. At this 
low concentration cuprizone fed in the diet manifests CNS demyelination without 
systemic toxicity, as measured by gross liver histology and liver function tests for 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, alkaline 
phosphatase and albumin (156, 158). During cuprizone treatment mice show lethargic 
movement, approximately 10% weight loss and altered gait (159). Demyelination and 
immune cell recruitment are monitored at the mid-line corpus callosum, at the fornix 
region. At the end of 5 weeks of cuprizone diet demyelination is complete but mice 
are fed cuprizone for one more week to ensure complete demyelination in all mice. 
After 6 weeks the mice are returned to normal chow to allow for remyelination. There 
is an increase in ODG progenitors during demyelination with maximum infiltration 
after 5 weeks of cuprizone treatment and by the end of 9 weeks of start of treatment 
remyelination is complete. Untreated control mice were maintained on a diet of 
normal pellet chow.   
There are several advantages of the cuprizone model: 1) It exhibits type III 
and IV MS neuropathology characterized by microglial infiltration and astrogliosis in 
the absence of T cell infiltrates thus allowing for study of the role of the innate 
immune system of the CNS in neuroinflammation 2) Both demyelination and 
remyelination follow a predictable time course 3) Cuprizone-induced demyelination 
occurs at major nerve tracts such as the corpus callosum and cerebellar peduncles that 
can be located easily and studied reproducibly. 4) Cuprizone can be easily 
administered through ground chow.  
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Figure 1.3. Schematic of cuprizone-induced model of CNS demyelination 
Our laboratory uses cuprizone to induce demyelination in the brain of C57Bl/6 mice as a model for MS. Mice 
are fed 0.2 % cuprizone mixed in ground chow ad libidum for 6 weeks after which they are returned to normal 
chow to allow for remyelination. Demyelination is maximal at 5 weeks of cuprizone treatment and 
remyelination is complete 10 weeks after starting treatment (4 weeks after cuprizone withdrawal).  
B. Experimental Autoimmune Encephalomyelitis (EAE) is a widely used 
model of MS. EAE is induced in mice by active priming with whole myelin proteins 
or specific myelin peptide epitopes in adjuvant. EAE can also be induced by adoptive 
transfer of myelin-specific CD4+ T cells. The symptoms of EAE are varied and can 
mimic different clinical manifestations of human MS. Unlike the cuprizone model, in 
EAE, the blood brain barrier is breached and myelin damage is T-cell mediated.      
During MS an autoimmune attack is triggered against myelin. This is characterized 
by recruitment and proliferation of microglia and astrocytes, release of pro-inflammatory 
cytokines such as IL-1ȕ, IL-18 and TNFĮ, demyelination, death of the myelin-producing 
ODG cells and axonal loss. IL-1ȕ levels in the cerebrospinal fluid (CSF) of MS patients 
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correlates with disease susceptibility, severity and progression (160, 161). IL-1ȕ
immunoreactivity has been shown in activated microglia and macrophages during EAE in 
rats (162). Treatment with either soluble IL-1 receptor (sIL-1R) or IL-1 receptor antagonist 
(IL-1Ra) reduced clinical signs of EAE in rats (162, 163). IL-1ȕ is cytotoxic to mature 
oligodendrocytes both in vivo and in vitro and causes proliferation of both microglia and 
astrocytes. Moreover, IL-18 levels are elevated in demyelinating cerebral lesions of MS 
patients and mice with a deletion of IL-18 (IL-18
-/-
) are resistant to EAE. Expression of IL-18 
and its receptor on oligodendrocytes is greater in brain tissue from patients with active MS 
than in patients with silent MS or from neuropathologically normal subjects. 
Role of NLRs in other diseases of the CNS: 
As described previously in this section mutations in NLRP3 in humans leads to three 
autoinflammatory syndromes - FCAS, MWS and CINCA that are collectively referred to as 
CAPS(52-56). All CAPS are characterized by increased levels of IL-1ȕ in the absence of 
infection. CINCA patients often display chronic aseptic meningitis which is reversed after 
treatment with the IL-1ȕ receptor antagonist Anakinra (164). This is indicative of a role for 
NLRP3 in neuroinflammation.   
1.8 NLRS IN REMYELINATION  
Regulation of oligodendrogenesis by progenitors is a potential therapeutic 
intervention for functional loss after demyelination in MS.  Previous studies have shown that 
remyelination is dramatically reduced in IL-1ȕ-/- mice in the cuprizone model (158). This 
reduction in remyelination was attributed to defect in generation of mature GSTpi
+
 mature 
ODG cells in spite of normal accumulation of NG2
+
 ODG progenitor cells (158). It was 
proposed that IL-1ȕ regulates remyelination via regulation of IGF-1 which is critical for 
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conversion of ODG progenitors to mature oligodendrocytes (165).  Subsequent studies with 
transgenic mice that expressed IGF-1 constitutively, confirmed the role of IGF-1 in inhibition 
of mature ODG death by apoptosis (166, 167). Thus, it is possible that NLRs via their 
regulation of IL-1ȕ and IL-18 processing and consequently IGF-1 can regulate 
oligodendrogenesis and remyelination. 
1. 9 NLRS AS POTENTIAL PHARMACOLOGICAL TARGETS IN 
NEURODEGENERATIVE DISEASES 
Activation of the various inflammasome complexes discussed here leads to activation 
of caspase-1 and subsequent production of the proinflammatory cytokines IL-1ȕ and IL-18. 
While specific drugs interfering with inflammasome components are under development, 
there have been several clinical studies exploring the modification of the IL-1ȕ pathway 
owing to its central role in several diseases. Modulation of IL-1ȕ function has been 
approached at 3 levels: firstly, the release of IL-1ȕ can be blocked by inhibition of upstream 
pathways (168, 169), secondly, the released cytokine can be neutralized or its receptor 
blocked to prevent downstream signaling (168, 170), and finally, the signaling mechanisms 
in the target cells can be blocked by disrupting further downstream signaling pathways (171-
176). A detailed list of the available drugs targeting the above mentioned steps of regulation 
for the IL-1ȕ pathway along with their mechanism of action is provided in Table 1.2. There 
are some caveats in the use of some of the inhibitors since they can inhibit not only the IL-1ȕ
but also the IL-18 pathways. A better understanding of the underlying mechanism for each 
disease would provide more accurate targets.  Target specificity would also enable a more 
accurate control of pathology. CAPS symptoms remain the gold standard, which can be 
reversed by treatments of the IL-1 receptor antagonist Kineret
®
. While some of these drugs 
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are efficacious in relieving symptoms (170, 172-176), several others are in clinical trials or 
remain to be tested in humans awaiting further studies of their mode of action and/or effects 
in animal models of disease (168, 169).  
Action Target Drug  
(Company) 
Description Reference 
Suppression of IL-1ȕ
production: 
Caspase-1 inhibition Caspase-1 Pranalcasan 
(Aventis/Vertex) 
VX-740; VX-765 (168) 
IL-1ȕ
posttranslational  
processing 
Unknown CP424174, CP412245 
(Pfizer) 
Diarylsulphonyl 
urea
(168) 
IL-1ȕ production 
inhibitor
Unknown CJ14877, CJ14897 
(Pfizer) 
Pyridine-2-
carboxylates
(168) 
Unknown LL-Z1217a 
(Pfizer) 
Terpenoid lactone (168) 
Suppression of IL-1ȕ
release:
    
IL-1ȕ release 
inhibitors
Unknown CP424174  
(Pfizer) 
Diarylsulphonyl 
urea
(168)) 
Neutralization of 
secreted IL-1ȕ:
    
IL-1  Anakinra  
(Kineret, Amgen) 
rhuIL-1Ra (168) 
IL-1 IL-1trap 
(Regeneron/Novartis) 
Human IL-
1R1:IgG1 protein 
(168) 
IL-1 CDP-484 
(Celltech)
PEGylated Antibody (168) 
Inhibition of IL-1R 
signal transduction: 
    
MyD88 inhibitors MyD88 † hydrocinnamoyl-l-
valyl pyrrolidine 
MyD88 mimic (70, 73) 
 † ST2825 
(Sigma-Tau) 
Peptidomimetic (172)  
IRAK-4 inhibitors IRAK-4 † Names unavailable Amides, 
imidazo[1,2-
a]pyridine 
compounds 
(76-78) 
† May also inhibit IL-18R and TLR signal transduction 
TABLE 1.3 Pharmacological inhibitors targeting IL-1ȕ production, release or action   
1. 10 CONCLUDING REMARKS 
The association of the NLRs with several immunological diseases suggests a role for 
these proteins in both innate and adaptive immunity. Recent studies are beginning to unfold 
the role of this family in immune regulation and dysregulation however, a plethora of 
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questions remain unanswered.  Firstly how is the diversity of PAMPs and DAMPs sensed 
and differentiated from self molecules? Secondly how does such a wide range of symptoms 
in CAPS arise from mutations that are relatively clustered in the NBD of NLRP3? Thirdly is 
there a cross talk between the different inflammasome pathways and do they compensate for 
each other?  Finally what are the DAMPs and PAMPs that might activate the inflammasome 
pathways in complex immune diseases such as type II diabetes, multiple sclerosis and 
atherosclerosis? Considering the vibrant research in this field, significant progress is likely to 
resolve several of these issues. 
CHAPTER II 
NLRP3 REGULATES NEUROINFLAMMATION AND THE CLEARANCE OF MYELIN 
DEBRIS IN THE CNS 
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2.1 ABSTRACT 
Sterile inflammation is increasingly recognized as an important contributor to a host of CNS 
disorders however its regulation in the brain remains poorly understood.  NLRP3 is a key 
component of the inflammasome complex which also includes ASC and procaspase-1.  In the 
immune system, inflammasome formation is primarily triggered by membrane P2X7R
engagement leading to cleavage-induced maturation of caspase-1 and IL-1ȕ/IL-18. This work 
shows that expression of the Nlrp3 gene was increased over 100 fold in a neurotoxin 
(cuprizone)-induced demyelination and neuroinflammation model.  Mice lacking the Nlrp3
gene exhibited reduced neuroinflammation, demyelination and oligodendrocyte loss in this 
model. This outcome is also observed for mice lacking caspase-1, while mice lacking IL-1ȕ
were indistinguishable from wild-type controls indicating that the Nlrp3-mediated function is 
independent of IL-1ȕ. The absence of P2X7R reduced neuroinflammation but not 
demyelination suggesting that this pathway does not affect the latter.  Further analyses 
revealed that macrophages from Nlrp3
-/-
 and casp1
-/-
mice but not controls exhibited 
augmented capacity to phagocytize myelin and clear myelin debris.  This difference did not 
extend to latex beads or bacteria which agrees with the differential regulation of distinct 
phagocytosis pathways. These results suggest that NLRP3 plays an important role in a 
neurologic disease model by exacerbating CNS inflammation but also by a novel function 
evoking myelin clearance.  Thus the therapeutic inhibition of NLRP3 might not only reduce 
sterile CNS inflammation but also enhance the clearance of CNS debris which has broad 
implications for resolving other CNS diseases.    
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2.2 INTRODUCTION 
Sterile inflammation refers to inflammation that is not caused by microbial pathogens, 
and is recognized as a key component of many neurological diseases including multiple 
sclerosis (MS), Parkinson’s disease, and Alzheimer’s disease. MS results from 
neuroinflammation characterized by infiltration of microglia and astrocytes, enhanced 
expression of cytokines/chemokines, demyelination and axonal loss (148, 149). An 
understanding of the mechanisms by which neuroinflammation affects demyelination is 
necessary to identify potential therapeutic targets.      
Several families of innate immune receptors or sensors have been identified, with the 
NLR genes receiving significant attention due to their genetic linkage to human immunologic 
diseases and their role in immune regulation (1, 2). Among NLRs, NLRP3 represents a core 
component of a caspase-1-activating inflammasome complex, comprised of an NLR protein, 
the adaptor molecule ASC (Apoptosis associated Speck-like protein containing a CARD) and 
procaspase-1 (20, 177).  Activated caspase-1 in turn cleaves and activates over seventy 
substrates including the proinflammatory cytokines interleukin-1beta (IL-1ȕ) and IL-18 (18, 
19). NLRP3 forms an inflammasome in response to bacterial RNA and toxins (8, 21), ATP 
(9), uric acid (10), hyaluronan (22), amyloid-ȕ (12), asbestos, silica (23, 24) and alum (23, 
25). Mutations in the human NLRP3 gene have been identified in dominantly-inherited 
autoinflammatory syndromes collectively referred to as CAPS (Cryopyrin-associated 
Periodic Syndromes) (56, 122) characterized by hyperactivation of the inflammasome 
complex and increased IL-1ȕ (56, 164).  CAPS symptoms have been reversed by treatments 
with the IL-1 receptor antagonist Kineret
®
(178).  Although the role of NLRP3 in CAPS is 
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well known, its role in other inflammatory diseases, including CNS inflammation, is less 
understood.
In this study we utilized the cuprizone-induced mouse model of demyelination to 
evaluate the role of NLRP3 in sterile CNS inflammation.  This model has several advantages: 
1) It exhibits type III and IV MS neuropathology characterized by microglial infiltration and 
astrogliosis in the absence of T cell infiltrates (147); 2) it is easily induced by administering 
cuprizone through the chow; 3) the disease course follows a predictable time course, and 4) 
demyelination has a reproducible pathology involving major nerve tracts such as the corpus 
callosum and cerebellar peduncles that are easily located (156).  Using the cuprizone model, 
we studied mice deficient in genes encoding NLRP3 (Nlrp3
-/-
), caspase-1 (casp1
-/-
), IL-1ȕ
(IL-1ȕ-/-), IL-18 (IL-18-/-), and P2X7R (P2X7R-/-) as a way to examine the role of the NLRP3 
inflammasome complex in neuroinflammation and demyelination in vivo. We found a 
significant role for the NLRP3 inflammasome pathway in the activation of 
neuroinflammation, but we also found an additional function for this pathway in the 
clearance of myelin debris.
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2.3 MATERIALS AND METHODS 
Mice.
Nlrp3
-/-
mice were provided by Millennium pharmaceuticals through Drs. Fayaz 
Sutterwala and Richard Flavell (Yale University), and were further backcrossed to C57BL/6 
mice for a total of nine generations. Casp1
-/-
were provided by Dr. Richard Flavell. P2X7R
-/-
were obtained from Beverly Koller (UNC-CH). C57BL/6 mice (WT) were purchased from 
the National Cancer Institute (Bethesda, MD) and Jackson Research Labs (Bar Harbor, ME). 
All mice were 8-10 weeks old prior to the start of treatment. All animal procedures 
conducted were approved by the Institutional Animal Care and Use Committee of UNC at 
Chapel Hill.  IL-1ȕ-/- mice were kindly provided by Dr. David Chaplin (University of 
Alabama, Birmingham) (179). Breeder pairs for IL-18
-/-
mice were purchased from Jackson 
laboratories (Bar Harbor, ME) and bred in house to generate mice needed for our studies. 
Cuprizone treatment. 
  8-10 weeks old male mice were fed 0.2% cuprizone [oxalic 
bis(cyclohexylidenehydrazide)] (Aldrich, St. Louis, MI) mixed into ground chow ad libidum
for 6 weeks to induce progressive demyelination. Untreated control mice were maintained on 
a diet of normal pellet chow. During cuprizone treatment mice showed lethargic movement, 
weight loss (Fig 2.10), ruffled hair and altered gait as described earlier (158, 159)
Tissue preparation.
Mice were deeply anesthetized and intra-cardially perfused with phosphate-buffered 
saline (PBS) followed by 4% paraformaldehyde (PFA). Brains were removed, post-fixed in 
PFA, and embedded in paraffin. 5-µm coronal sections were cut at the fornix region of the 
corpus callosum. For frozen sections, mice were perfused and post-fixed as described earlier. 
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Brains were allowed to sink in 30% sucrose in PBS and snap frozen on dry ice in OCT. 5µm
and 20µm coronal sections were cut at the fornix region of the corpus callosum for 
immunohistochemistry (IHC) and in situ hybridization respectively. All analyses were 
restricted to the mid-line corpus callosum as described previously (158, 180, 181).
Staining.
To examine demyelination, paraffin sections were rehydrated through a graded series 
of alcohol washes and stained with Luxol fast blue-periodic acid-Schiff’s base (LFB-PAS; 
Sigma, St. Louis, MI) as described previously (158, 180, 181). Sections were read by three 
double-blinded readers and graded on a scale from 0 (complete myelination) to 3 (complete 
demyelination). Higher scores indicate greater pathology. For the detection of 
microglia/macrophages, tissue sections were rehydrated and permeabilized with 0.1% 
Triton/PBS for 20 min at room temperature and then incubated with Ricinus communis
agglutinin-1 (RCA-1) lectin (1:500, Vector, Burlingame, CA) at 37 °C for 1hr. Only RCA-1
+
cells with observable 4', 6’-diamidino-2-phenylindole (DAPI) stained nucleus were included
in the quantification.
Immunohistochemistry (IHC). 
IHC was performed on 5-µm paraffin embedded sections that were deparaffinized 
and rehydrated through alcohols as described earlier. For the detection of mature 
oligodendrocytes, the sections were processed by boiling in antigen unmasking solution 
(1:100, Vector, Burlingame, CA) for 13 min in a microwave. These sections were 
permeabilized with 0.1% Triton/PBS for 20 min and incubated with 2% normal goat serum 
in 0.1% triton-PBS for 20 min at room temperature. Subsequently, the sections were 
incubated with rabbit anti mouse polyclonal antibody anti- GSTʌ (1:500, Stressgen, Ann 
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Arbor, MI) at 4°C overnight. Sections were then washed in PBS and incubated with the 
appropriate biotinylated antibody against primary antibody (1:100, Vector, Burlingame, CA) 
and texas red-conjugated avidin (1:500, Vector, Burlingame, CA). The sections were washed 
and incubated with Alexa Fluor conjugated 594.  To detect astrocytes, sections were 
incubated with 5% normal goat serum in 0.1% triton-PBS for 20 min at room temperature. 
Subsequently, the sections were washed and incubated with rabbit anti-cow monoclonal 
antibody (1:100, DAKO) and goat-anti-rabbit-fluorescein conjugated secondary antibody 
(1:100, Vector, Burlingame, CA).  For the detection of myelin basic protein (MBP) sections 
were permeabilized with 0.1% Triton/PBS for 10 min and incubated with 5% normal goat 
serum in 0.1% triton-PBS for 20 min at room temperature. Subsequently, the sections were 
incubated with mouse monoclonal antibody anti-MBP (1:1000, Steinberger) at 4°C 
overnight. Sections were then washed in PBS and incubated with anti-mouse IgG conjugated 
with texas red (1:1000, Vector, Burlingame, CA) for 45mins at room temperature.  For the 
detection of 2’, 3’-cyclic nucleotide phosphodiesterase (CNPase), the sections were 
processed by boiling in antigen unmasking solution (1:100, Vector, Burlingame, CA) for 13 
min in a microwave. These sections were permeabilized with 0.1% Triton/PBS for 20 min 
and incubated with 5% normal goat serum (NGS) in 0.1% Triton-PBS for 20 min at RT. 
Subsequently, the sections were incubated with chicken polyclonal antibody to CNPase 
(1:500, chemicon, Billerica, MA) at RT for 1h. Sections were then washed in PBS and 
incubated with rabbit polyclonal to chicken IgY biotin (1:500, Abcam, Cambridge, MA) for 
1h at RT. After PBS washes the sections were incubated with Alexa 594-conjugated avidin 
(1:500, Invitrogen) for 1h at RT. 
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Immunopositive cells with an observable DAPI stained nucleus were counted blindly 
twice. Cell counts are averages of at least 9 and up to 14 mice per time point.  
Imaging.
All cell counts are within the mid line of the corpus callosum, confined to an area of 
0.033 mm
2
. An Olympus BX-40 microscope with camera (optronics engineering) and Scion 
image acquisition software was used for taking images.   
Reverse transcription-PCR and quantitative real-time reverse transcription-PCR.
Total RNA was isolated from a dissected region of the brain containing the corpus 
callosum of wild-type and Nlrp3
-/ -
mice at several points during and after cuprizone 
treatment. RNA isolation was performed using Trizol reagent (Ambion) under RNase-free 
conditions (158). 
In situ Hybridization. 
3 mice per time point were perfused with PBS followed by a solution of 4% PFA.
20-µm OCT embedded frozen sections were cut at the fornix region of the corpus callosum. 
These sections were processed for in situ hybridization at the UNC neuroscience center in
situ hybridization core.
Primary cell culture.
Bone marrow derived macrophages were extracted from femurs of WT, Nlrp3
-/-
and
casp1
-/-
mice.  The cells were cultured as described previously (182).
Phagocytosis Assays.
A schematic for all the phagocytosis assays is provided in figure 2.7 a. For 
phagocytosis of fluorescent beads, 0.25×10
6
 cells per well were incubated with 0.25×10
8
beads for 0, 30, 60 and 120 minutes at 37°C. Each experimental set consisted of an untreated 
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control and a negative control for phagocytosis, treated with 10µM cytochalasin D a known 
inhibitor of phagocytosis. For myelin phagocytosis experiments, myelin was extracted from 
adult C57BL/6 mouse brains as described previously. A schematic of myelin extraction from 
adult mouse brain is provided in figure 2.7b. Myelin was labeled with the lipophilic dye 1, 
1’-dioctadecyl-3, 3, 3’, 3’-tetramethylindocarbocyanine perchlorate (DiI; Molecular probes: 
SKU# D-282) as described previously. 0.25× 10
6
 cells/well in 24-well culture dish was 
incubated with 20µg labeled myelin for 0, 30, 60 and 120 minutes at 37°C. After 
phagocytosis non- ingested myelin was removed by washing the cells twice with media and 
once with PBS. For Escherichia coli (E. coli) phagocytosis experiments, E. coli strain 
O114:B4 (ATCC) transformed with the pEGFP plasmid (Clontech), to express GFP were 
kindly provided by our collaborator Dr. Glenn Matsushima. E. coli were cultured to log 
phase in Luria broth (LB) containing ampicillin. 0.25× 10
6
 cells/well in 24-well culture dish 
were incubated with 0.25× 10
8
E. coli for 0, 30, 60 and 120 minutes at 37°C.  After 
phagocytosis non-ingested E. coli were removed by washing the cells twice with media and 
once with PBS.  
The internalization of myelin beads or E. coli was quantified by measuring the mean 
cellular fluorescent intensity by flow cytometry. A Beckman coulter (Dako) CyAn ADP flow 
cytometer was used for all the above mentioned experiments. Experiments were repeated at 
least four times and the significance was determined by using student’s t-test. Differences 
were considered statistically significant if p < 0.05. 
Confocal microscopy was used to visualize myelin and bead phagocytosis by 
macrophages. For this, 0.25×10
6
 cells were plated on 24 well glass bottom plates and after 2 
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hours of phagocytosis, the cells were washed thrice with PBS and fixed with 2% 
paraformaldehyde for 10 minutes. Subsequently, cells in the wells were stained with RCA as 
described previously in the staining section.  A Zeiss LSM5 Pascal confocal laser scanning 
microscope was used for all the confocal microscopy. 
Protein analysis.
Total protein was extracted from the forebrains of cuprizone-treated and untreated 
control C57BL/6 mice. Briefly, corpus callosi were homogenized on ice in 600µl of RIPA 
buffer containing protease inhibitors. The homogenate was centrifuged at 10000g for 15mins 
at 4°C. Supernatants were used for further analyses.  For protein extraction from cultured 
cells, 0.25×10
6
 cells were lysed in 0.25 ml RIPA buffer by rotating cell at 4°C for 20 minutes 
followed by centrifugation at 13100rpm for 20 minutes. The supernatants were used for 
further analyses. Protein concentrations were determined using a coomasie (Bradford) 
protein assay kit (Pierce).  IL-1ȕ levels were determined by ELISA (optiEIA ELISA, BD).     
Transmission electron microscopy (TEM).
3 mice per time point were perfused with PBS followed by a solution of 4% PFA and 
2.5% glutaraldehyde. Brains were sliced into 1-mm sections, and the section corresponding 
to the region of the fornix was trimmed and reoriented so that a cross-section of the corpus 
callosum was achieved. Thin sections were cut, stained with uranyl acetate and lead citrate 
and analyzed as previously described.
Statistical Analysis.
Data are expressed as mean s.e.m. Unpaired Student's t tests were used to 
statistically evaluate significant differences. Differences were considered statistically 
significant if p < 0.05.
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2.4 RESULTS 
Nlrp3 expression is increased in the cuprizone model of demyelination 
Nlrp3 transcript expression in the CNS of cuprizone treated C57BL/6 mice was 
examined by real-time PCR amplification.  It was found to increase progressively to more 
than 120 fold by the 4 week time point of a course of cuprizone-induced demyelination (Fig. 
2.1a). This increase coincided with the peak of inflammatory cell infiltration, demyelination 
and mature oligodendrocyte death. Since commercial antibodies for mouse NLRP3 are of 
poor quality, we evaluated the production of IL-1ȕ as a surrogate indicator of NLRP3 protein 
activation.  Protein lysates from corpus callosi of cuprizone treated mouse brains analyzed by 
ELISA showed a similar increase in IL-1ȕ protein as Nlrp3 mRNA, supporting a functional 
increase in NLRP3 activity (Fig. 2.1b). Moreover, these studies corroborate results from an 
earlier study that quantified the number of IL-1ȕ+ cells during cuprizone-induced 
demyelination and remyelination (165).  To further assess Nlrp3 expression, we also 
analyzed Nlrp3 expression in control untreated and 5 week cuprizone treated brains of 
C57BL/6 control and Nlrp3
-/-
mice as negative control by in situ hybridization using a 
digoxigenin labeled antisense probe to detect Nlrp3. A sense strand probe was also included 
as negative control. Nlrp3 expression is evident in untreated C57BL/6 control brains (Fig. 
2.1c).
Recruitment of microglia and astrocytes is delayed in Nlrp3
-/-
 mice 
To explore if NLRP3 has a role during cuprizone-induced sterile inflammation, we 
used mice lacking the Nlrp3 gene.  WT and Nlrp3
-/-
 mice showed similar reduction in weight 
during the course of cuprizone treatment (Fig. 2.9). We first examined if deletion of this gene 
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in mice had an effect on microglial accumulation and astrogliosis (Fig. 2.1c-f).  Microglia are 
resident immune cells of the CNS (183). Activated microglia can phagocytose myelin debris, 
present antigens to T cells, and release cytokines and chemokines (183, 184). Activated 
astrocytes and microglia perform several overlapping roles during neuroinflammation (185). 
Microglial and astroglial populations at the corpus callosum were identified by Ricinus
communis agglutinin-1 (RCA-1) lectin and glial fibrillary acidic protein (GFAP) staining, 
respectively (Fig. 2.1d-e). Untreated, age-matched (0 Wk) Nlrp3
-/-
mice and C57BL/6 (WT) 
controls showed no difference in the quantitation of microglia and astrocytes at the corpus 
callosum (Fig. 2.1d-g).  A histological representation of these data is shown in Figs. 2.1d-e, 
and quantitation is shown in Figs. 2.1f-g.  At 3, 3.5 and 4 weeks of cuprizone treatment, there 
was a progressive and significant (P= 0.02 at 3 Wks, P= 0.05 at 3.5 Wks, P= 0.01 at 4 Wks) 
reduction in microglial infiltration in Nlrp3
-/-
mice relative to WT controls (Fig.2.1f). 
Similarly, there was a progressive and statistically significant reduction in astrogliosis in the 
Nlrp3
-/-
 mice at weeks 3 and 4 of cuprizone treatment (Fig. 2.1g, P=0.03 at 3 Wks, P=0.001
at 4 Wks). These results indicate that NLRP3 enhances microglia accumulation and 
astrogliosis in the affected tissues. After 5 weeks of cuprizone treatment, microglial 
accumulation and astrogliosis between Nlrp3
-/-
and C57BL/6 control animals were similar 
(Fig. 2.1f-g). This is consistent with other studies of the cuprizone model wherein the 
removal of inflammatory genes has not affected neuropathology after this time point (158, 
165).
Demyelination is delayed in cuprizone-treated Nlrp3
-/-
 mice
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A second component of the cuprizone model that is relevant to human diseases is the 
demyelination process. To assess if NLRP3 plays a role in demyelination and in the loss of 
mature oligodendrocytes, Nlrp3
-/-
 mice along with age matched WT control mice were 
treated with cuprizone for 3, 3.5, 4 and 5 weeks.  Representative scoring of the extent of 
demyelination as measured by Luxol fast blue-periodic acid Schiff (LFB-PAS) staining is 
shown in Fig. 2.2a. Slides were read by three blinded readers on a scale of 0 (no 
demyelination) to 3 (complete demyelination). WT mice showed significant demyelination 
initiating at the 3 week time point and continuing to the end of the study at the 5 Wk time 
point (Fig. 2.2b). Nlrp3
-/-
mice showed a significant delay in demyelination at the 3, 3.5 and 
4 week time points when compared to WT controls (Fig. 2.2b). LFB is a screening assay for 
myelin which requires further verification with more specific stains such as glutathione S 
transferase pi subunit (GSTʌ), a marker of the mature oligodendrocyte population. Prior to 
cuprizone treatment (0 Wk), Nlrp3
-/-
mice and WT controls showed no difference in mature 
oligodendrocyte populations at the corpus callosum as shown in Fig. 2.2c.  After 3, 3.5 and 4 
weeks of cuprizone treatment, the reduction of mature oligodendrocytes was attenuated in 
Nlrp3
-/-
mice relative to C57BL/6 controls. A quantitation of the composite data is shown in 
Fig. 2.2d (P=0.004 at 3 Wks, P=0.02 at 3.5 Wks and P=0.002 at 4 Wks). After 5 weeks of 
cuprizone treatment, Nlrp3
-/-
and WT control mice showed no difference in demyelination 
and mature oligodendrocyte death (Fig. 2.2d).  Together, these data indicate that NLRP3 
delays demyelination but does not obviate this process.  This is consistent with studies of 
other inflammatory genes in the cuprizone model (158, 165, 180, 181).  As an additional 
analysis of oligodendrocytes, a CNPase stain was performed and showed similar results (Fig. 
2.2e).
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Demyelination, mature oligodendrocyte death, astrogliosis and microglial infiltration 
during cuprizone-induced demyelination are independent of IL-1ȕ
The above results indicate the importance of NLRP3 in pathology associated with the 
cuprizone model; hence we examined the role of an inflammasome end-product, i.e. IL-1ȕ, in
this model. An earlier study of IL-1ȕ-/- mice showed delayed remyelination but no difference 
in demyelination in the cuprizone model, although this latter issue was only peripherally 
addressed in that report (165).  To elaborate on these results, we performed a more extensive 
analysis of cuprizone-induced demyelination in IL-1ȕ-/- mice.  IL-1ȕ-/- mice showed no 
difference in demyelination (Fig. 2.3a), loss of GSTʌҙ mature oligodendrocyte (Fig. 2.3b), 
accumulation of microglia (Fig. 2.3c) or astrogliosis (Fig. 2.3d) during demyelination. This 
indicates that all of the measured neuropathology observed in the cuprizone model is IL-1ȕ
independent.
Cuprizone-induced microglial accumulation, astrogliosis and demyelination are caspase-1 
dependent
NLRP3 is required for the processing of caspase-1, which in turn cleaves IL-1ȕ and 
IL-18 (Sutterwala et al., 2006).  To establish if NLRP3-dependent CNS inflammation and 
demyelination are caspase-1 dependent, we studied casp1
-/-
mice. casp1
-/-
 and WT mice 
showed a statistically significant difference in the extent of demyelination as measured by 
LFB (Fig. 2.4a) and in the number of mature oligodendrocyte as detected by GSTʌ
immunostaining after cuprizone treatment (Fig. 2.4b).  casp1
-/-
mice also showed delayed 
microglial infiltration and astrogliosis when compared to WT controls (Fig. 2.4c and d). 
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These results suggest that the phenotype of casp1
-/-
mice is similar to mice deficient in the 
Nlrp3 gene. 
The role of IL-18 in demyelination and neuroinflammation 
Age-matched untreated (0 Wk) IL-18 
-/-
mice and C57BL/6 WT controls showed no 
difference in numbers of microglia and astrocytes at the corpus callosum (Fig 2.5c-d). At 
3weeks of cuprizone treatment there was progressive and significant reduction (p< 0.05)  in 
microglial infiltration in IL-18
-/-
mice relative to WT controls (Fig. 2.5e). Similarly, there 
was an overall trend of reduced astrogliosis in the IL-18
-/-
 mice at week 3. After 4 and 5 
weeks of cuprizone treatment there was no difference in microglial accumulation and 
astrogliosis between IL-18
-/-
and C57BL/6 controls (Fig. 2.5e-f). To study the role of IL-18 
in demyelination we utilized staining for myelin and mature ODGs. WT mice showed 
significant demyelination initiating at the 3 week time point and continuing to the end of the 
study at the 5 week time point (Fig 2.5b).  IL-18
-/-
mice showed a significant delay in 
demyelination at the 3 week time point when compared to WT controls (Fig 2.5b). Further
verification with GSTʌ , a marker of mature ODG population showed that prior to cuprizone 
treatment (0 Wk) IL-18 
-/-
mice and C57BL/6 controls showed no difference in mature ODG 
populations at the corpus callosum as shown in Fig. 2.5c.  At 3 weeks of cuprizone treatment, 
the reduction of mature ODGs was attenuated in IL-18
-/-
mice relative to C57BL/6 controls. 
A quantitation of the composite data is shown in Fig. 2.5d. After 4 and 5 weeks of cuprizone 
treatment, there was no difference in demyelination and mature ODG death between IL-18
-/-
and C57BL/6 control mice (Fig. 2.5d) indicating that IL-18 delayed demyelination but did 
not obviate this process.
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Cuprizone-induced microglial accumulation and astrogliosis but not demyelination is 
dependent on P2X7R
ATP mediated activation of P2X7R, a membrane associated ATP-gated ion channel, 
has been linked to the activation of the NLRP3 inflammasome and consequently to the 
activation of caspase-1 and IL-1ȕ release (9).  To test if cuprizone-induced 
neuroinflammation is dependent on the engagement and activation of P2X7R, we examined 
P2X7R
-/-
mice (186).  Demyelination, mature oligodendrocyte number, microglial infiltration 
and astrogliosis were studied in the cuprizone model as described earlier. P2X7R
-/-
 and WT 
controls showed no difference in the kinetics or extent of demyelination or mature 
oligodendrocyte depletion (Fig. 2.6a and b).  However, P2X7R
-/-
 mice showed significantly 
reduced microglial infiltration and astrogliosis (Fig. 2.6c and d, P=0.005 and P <0.05 
respectively).  These results indicate that P2X7R is involved in the inflammatory response 
observed in the cuprizone model, but not with the demyelination process.   

Myelin phagocytosis is enhanced in Nlrp3
-/-
macrophages
The data presented thus far suggest that NLRP3, caspase-1 and P2X7R all exacerbate 
the extent of inflammation as measured by microglial activation and astrogliosis.  However, 
NLRP3 and caspase-1 also mediate a function that is distinguishable from IL-1ȕ and P2X7R
in the eventual loss of myelin and mature oligodendrocyte numbers.  Microglia/macrophages 
and astrocytes are active sensors of the CNS milieu where they sample their environment by 
highly mobile processes (such as filopodia) (183).  Microglia sense their environments 
through surface receptors or intracellular sensors after phagocytosis. During demyelination, 
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microglia are responsible for several proinflammatory as well as anti-inflammatory roles, one 
of the most important being the removal of myelin debris by phagocytosis (184, 187). 
Removal of myelin debris is critical for the resolution of inflammation, death of 
oligodendrocytes and recruitment of oligodendrocyte progenitors for remyelination (135, 
184).  To investigate the role of NLRP3 in myelin phagocytosis, macrophages were isolated 
from WT, Nlrp3
-/-
and casp1
-/-
mice.  We first established conditions for the phagocytosis of 
latex beads, bacteria and myelin.  A schematic for the experimental design is provided in Fig 
2.7. Macrophages from C57BL/6 mice readily phagocytized fluorescent latex beads (Fig. 
2.8a, second row). Treatment with cytochalasin D (cytD), a known inhibitor of phagocytosis, 
was used as a negative control for all treatment groups (Fig. 2.8a; also Fig. 2.10c). Similarly, 
these cells readily phagocytized E. coli (Fig. 2.8a, fourth and fifth rows) and myelin (Fig. 
2.8a, bottom two rows).  Myelin phagocytosis was studied by incubating macrophages with 
myelin that was labeled with the fluorescent carbocyanine lipophilic dye 1, 1’-dioctadecyl-3, 
3, 3’, 3’-tetramethylindocarbocyanine perchlorate (DiI).  To explore if loss of the Nlrp3 gene 
affected phagocytosis, macrophages prepared from WT controls, Nlrp3
-/-
 and casp1
-/-
 were 
incubated with beads, E. coli or DiI-labeled myelin (Figs. 2.8b-d respectively) for 0, 30, 60 
and 120 min. Internalization was measured over time by flow cytometry.  Nlrp3
-/-
, casp1
-/-
and WT cells phagocytized beads or bacteria to a comparable extent with similar kinetics 
profiles (Figs. 2.8b and c).  In contrast, the internalization of DiI-labeled myelin was greatly 
increased in Nlrp3
-/-
 mice at all three time points when compared to control cells (Fig. 2.8d). 
Myelin phagocytosis by casp1
-/-
macrophages was also enhanced at two time points but not at 
the last time point.  These findings suggest that NLRP3 and caspase-1 negatively impacts 
myelin phagocytosis which is important for myelin clearance. An examination of P2X7R
-/-
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cells did not show such a decrease of myelin phagocytosis (not shown),  thus providing a 
mechanism to explain how NLRP3 and caspase-1 but not P2X7R exacerbate CNS disease 
outcome via a new pathway. 
Role of NLRP3 in remyelination     
Regulation of oligodendrogenesis by progenitors is a potential therapeutic 
intervention for the functional loss after demyelination in MS. Previous studies in the 
cuprizone model have shown that; 1) remyelination is dramatically reduced in IL-1ȕ-/-
mice(165), 2) IL-1ȕ regulates remyelination via regulation of IGF-1 which is critical for 
conversion of ODG progenitors to mature ODGs (165, 188) 3)Transgenic mice expressing 
IGF1 constitutively have reduced mature ODG death by apoptosis (166, 167). We 
hypothesized that NLRP3 via its regulation of IL-1ȕ processing and consequently IGF-1 may 
regulate oligodendrogenesis and remyelination. Our data with Nlrp3
-/-
 mice during 
remyelination (8, 10 and 12 week time points) indicate that remyelination remains unchanged 
relative to C57Bl/6 controls by GST pi and LFB/PAS staining, and TEM analysis (Fig 2.9).






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2.5 DISCUSSION 
 The NLR genes, particularly those associated with the inflammasome function, have 
secured much interest as sensors of pathogen associated molecular patterns (PAMPs) as well 
as damage-associated molecular patterns (DAMPs); however, their roles in CNS 
inflammatory disorders have not been extensively studied (9, 10, 182). In this report we 
provide evidence that NLRP3 has a role in regulating neuroinflammation and demyelination 
in a mouse model of cuprizone-induced demyelination. However the outcome is much more 
complex than anticipated.  We found that one of the end products of the inflammasome, 
namely IL-1ȕ, has no role in any of the pathologic events that were investigated.
Conventional inflammasome components including NLRP3, caspase-1 and P2X7R all 
exacerbated inflammatory readouts such as microglial accumulation and astrogliosis, but 
only NLRP3 and caspase-1 enhanced demyelination and accelerated the loss of mature 
oligodendrocytes.  Additionally, a cell-based investigation indicates that NLRP3 and 
caspase-1 decreased the capability of macrophages to phagocytose and therefore clear myelin 
debris.  These data reveal a novel and important role for NLRP3 that has not been 
appreciated previously. 
NLRP3 is known for its classic role in the formation of a multi-protein complex with 
ASC and pro-caspase-1 that is critical for caspase-1 cleavage and maturation, which in turn is 
important for the processing of pro-IL-1ȕ/IL-18 to mature IL-1ȕ/IL-18.  In the CNS, IL-1ȕ is 
released primarily by microglia and macrophages (165). IL-1ȕ promotes leukocyte 
infiltration by inducing expression of many cytokines, chemokines and adhesion molecules 
(189). The release of IL-1ȕ also mobilizes neutrophils and other immune cells to aid in 
resolving infections and promoting wound healing. Chronic release of IL-1ȕ is detrimental as 
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it can contribute to skin rashes, inflammatory arthritis, and systemic fever (164). For this 
reason, IL-1ȕ production is tightly regulated at the levels of transcription, translation and 
release.  Previous studies examining the role of IL-1ȕ in neuroinflammation have not yielded 
consistent findings. IL-1ȕ levels in the cerebrospinal fluid (CSF) of MS patients correlate 
with disease susceptibility, severity and progression (160, 161). IL-1ȕ immunoreactivity has 
been found in activated microglia and macrophages during EAE in rats (162). Treatment with 
either soluble IL-1 receptor (sIL-1R) or IL-1 receptor antagonist (IL-1Ra) reduce clinical 
signs of EAE in rats (163, 190). IL-1ȕ is cytotoxic to mature oligodendrocytes both in vivo
and in vitro, while stimulating proliferation of both microglia and astrocytes (191).
However, IL-1ȕ-/- mice also display delayed remyelination indicating a reparative role of IL-
1ȕ (165).  Our study of IL-1ȕ-/- mice in the cuprizone model showed no differences in 
demyelination, microglial infiltration, astrogliosis or mature oligodendrocyte death after 0, 3, 
and 4 weeks of cuprizone treatment. This indicates that the demyelination observed in the 
cuprizone model is IL-1ȕ independent even though IL-1ȕ levels increase concurrent with 
inflammatory cell infiltration during demyelination (165).  
Since IL-1ȕ-/- mice did not replicate the demyelination as seen in Nlrp3-/- mice we 
explored the role of caspase-1 and IL-18 in demyelination. Caspase-1 has been implicated in 
both human and mouse neuroinflammation.  Caspase-1 levels are significantly increased in 
peripheral blood mononuclear cells from MS patients (44). Moreover, caspase-1 is known to 
contribute to the pathology of EAE (45, 46). Our studies with casp1
-/-
mice showed delayed 
microglial infiltration, astrogliosis, reduction in mature oligodendrocyte depletion and a 
delay in demyelination.
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IL-18 is an 18kDa member of the IL-1 family of cytokines. IL-18 is produced by several 
immune and non-immune cells including monocytes, macrophages, splenocytes, 
keratinocytes, microglia, macrophages and astrocytes (47-49). In the CNS, IL-18 induces 
microglial production of proinflammatory cytokines such as IL-1ȕ and TNFĮ and matrix 
metalloproteinases (MMPs). Extravasation of polymorphonuclear leukocytes (PMNs) and 
monocytes/macrophages is amplified by IL-18 dependent upregulation of intercellular 
adhesion molecule-1 (ICAM-1) on endothelial cells. IL-18 levels are elevated in 
demyelinating cerebral lesions of MS patients (192-194). Moreover, expression of IL-18 and 
its receptor on oligodendrocytes is greater in brain tissue from patients with active MS than 
in patients with silent MS or from neuropathologically normal subjects (195).  In 
experimental autoimmune encephalomyelitis (EAE) a murine model of MS in which the
induction of myelin basic protein (MBP)-specific CD4
+
 T cells secreting cytokines, 
particularly IFN-Ȗ and TNF-Į, results in limb paralysis, elevated IL-18 mRNA is seen in the
CNS of EAE rats at onset and during the disease (196, 197). However,  EAE studies with 
mice deficient in IL-18 (IL-18
-/-
) remain controversial, while Shi et al., reported that IL-18
-/-
mice are resistant to EAE (198), Gutcher et al., reported that IL-18
-/-
mice are susceptible to 
EAE  but IL-18 receptor Į deficient mice (IL-18RĮ-/-) are resistant to EAE indicating the role 
of a ligand other than IL-18 acting via IL-18RĮ to cause EAE (199). IL-18-/- mice replicated 
the data obtained with Nlrp3
-/-
 mice at the 3 week time point of demyelination. 
Several studies have shown that caspase-1 has numerous targets beside IL-1ȕ and IL-
18, with more than seventy substrates (18, 19).  The above results led us to explore 
mechanisms mediated by NLRP3 other than those mediated by loss of IL-1ȕ.  One possible 
mechanism is the role of NLRP3 in myelin phagocytosis.  This idea is largely stimulated by 
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the role reported for TLRs in phagocytosis, although we appreciate the controversy regarding 
those findings (200-202). Our data suggest that Nlrp3
-/-
 and casp1
-/-
macrophages show an 
increased ability to phagocytose myelin debris, but not latex beads nor bacteria.  This finding 
is important as it reflects a novel function for the NLRP3 protein.  Myelin phagocytosis is an 
important component of the pathology observed in both EAE and MS patients.  A prevailing 
model supported by data considers that clearance of myelin debris by macrophages and 
microglia is central to the repair mechanisms that follow demyelination in both central and 
peripheral nervous system diseases (136, 138, 177, 203, 204). Myelin debris can activate the 
complement system to form membrane attack complexes that disintegrate intact myelin 
(139). Moreover, myelin debris impairs remyelination in the adult rat CNS by inhibiting 
oligodendrocyte precursor cell differentiation (135). Therefore, myelin debris removal is 
critical for resolution of demyelination and for creating a pro-regenerative environment after 
demyelination. We provide evidence that bone marrow derived macrophages from Nlrp3
-/-
and casp1
-/-
 mice have increased myelin phagocytosis as compared to WT. This corroborates 
our in vivo data with Nlrp3
-/-
and casp1
-/-
 mice that showed delayed demyelination.  Thus,
Nlrp3
-/-
and casp1
-/-
 mice show an efficient removal of myelin debris which affects 
demyelination, myelin regeneration and oligodendrocyte recovery.  This implicates a new 
mechanism by which NLRP3 and caspase-1 might exacerbate neurodegeneration in vivo.
It remains unclear how NLRP3 exerts its effects on phagocytosis. There are several 
receptor complexes that are involved in myelin phagocytosis including scavenger receptors I 
and II (SR-A I/II) (143, 145), complement receptor 3 (CR-3), galectin-3 (144) and the Fc 
gamma receptor (FcȖR) (205).  It is possible NLRP3 affects any, some or all of these 
receptors by affecting their expression or signal transduction pathways required for optimal 
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myelin phagocytosis.  It is intriguing that NLRP3 does not negatively affect the phagocytosis 
of bacteria or latex beads.  This may have physiologic implications, since key host responses 
to bacterial infection are the uptake of bacteria by macrophages and the resultant production 
of IL-1ȕ.  Thus it would be counterproductive if NLRP3, a main route by which IL-1ȕ
maturation occurs to combat microbes, would then negate anti-bacterial responses by 
inhibiting bacterial phagocytosis.  Instead our data show that NLRP3 only affects the 
phagocytosis of myelin debris but not of bacteria, consistent with the anti-bacterial role of 
NLRP3.
The endogenous triggers of NLRP3 activation in the CNS and in the cuprizone-
induced model of demyelination remain undescribed. It is known that cell death at the site of 
inflammation or injury can cause increases of local ATP concentration to ranges of 1-10mM 
due to the release of cytoplasmic stores (123, 206). Unlike other P2X receptors, P2X7Rs are 
activated at concentrations of >1mM. Continuous ligation of P2X7R can lead to cell death by 
the formation of large pores in the cell membrane (128). These pores are formed by a P2X7R
associated protein, pannexin-1.  Recent research utilizing macrophages from Nlrp3
-/-
and
C57BL/6 mice demonstrated that pannexin-1 is critical for caspase-1 activation and IL-1ȕ
secretion in LPS-stimulated macrophages pulsed with ATP (128, 129).  In addition, P2X7R
deficient (P2X7R
-/-
) mice show suppression of EAE (130). Thus we tested the hypothesis that 
ATP released from cuprizone-induced apoptosis within oligodendrocytes might initiate 
NLRP3 inflammasome activation and propagation of demyelination.  However, our results 
with P2X7R
-/-
mice showed modestly delayed microglial infiltration and astrogliosis, but no 
effect on demyelination or oligodendrocyte numbers.  These results suggest that P2X7R
contributes to neuroinflammation, but not demyelination, in a modest way.  Thus activation 
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of P2X7R does not contribute to in vivo loss of oligodendrocytes in the cuprizone-induced 
model of demyelination.
In summary, the dual roles of NLRP3 in exacerbating neuroinflammation and 
inhibiting myelin debris clearance, along with a lack of its role in remyelination indicate that 
inhibition of NLRP3 may prove to be a valuable therapeutic approach for demyelinating 
diseases such as MS.  The results show that the neuroinflammatory component of the disease 
model is mediated by an NLRP3-, caspase-1- IL-18- and P2X7R-dependent pathway. 
However, the clearance of myelin debris is limited to NLRP3 and caspase-1.  This finding 
has broad implications for the clearance of CNS cellular debris in other acute and chronic 
degenerative diseases, including amyloid-ȕ in Alzheimer’s disease, myelin in mechanical 
injury involving axonal transection and in Guillain-Barré syndrome, cell debris in stroke, and 
dead synapses plus retinal ganglion cells in glaucoma and aging (184).    
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Figure 2.1- Increases in NLRP3 expression coincide with peak disease symptoms in the 
cuprizone model.  a. Nlrp3 mRNA increases during cuprizone-induced demyelination. 
Nlrp3 transcript was detected by real time PCR and the quantity at 0 Wk set to 1. Nlrp3
mRNA increased progressively reaching a maximum of ~120 fold after 5 weeks of cuprizone 
treatment concurrent with microglia/macrophage recruitment. b. Increase in IL-1ȕ release is 
concurrent with the increase in Nlrp3 expression during demyelination. IL-1ȕ release was 
measured by ELISA.  c. Nlrp3 is expressed in the adult mouse brain. Nlrp3 RNA was 
detected by in situ hybridization. d. Microglial recruitment to the corpus callosum was 
reduced in Nlrp3
-/-
 mice.  Microglia were detected by RCA lectin staining (red). DAPI was 
used to label nuclei (blue). e. Astrogliosis was reduced in Nlrp3
-/-
 mice.  GFAP (green) was 
used to detect astrocyte accumulation in the corpus callosum.  Inset shows isotype control for 
GFAP antibody. RCA
+
 or GFAP
+
 cells with an observable DAPI stained nucleus were 
counted blindly twice. Cell counts are averages of between 9 and 14 mice per time point. f.
Microglial infiltration was quantitated and found to be significantly reduced in Nlrp3
-/-
 mice 
(white bars) during demyelination (P= 0.02 at 3 Wks, P= 0.05 at 3.5 Wks, P= 0.01 at 4 Wks).
g. Astrocyte accumulation was quantitated and found to be significantly reduced in Nlrp3
-/-
mice during demyelination (P=0.03 at 3 Wks, P=0.001 at 4 Wks). In f-g, *P< 0.05, 
**P<0.01; n=9-14; error bars, s.e.m.  
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Figure 2.2- NLRP3 exacerbates demyelination and mature oligodendrocyte death in the 
corpus callosum during demyelination. a. The schematic depicts the scale for scoring of 
demyelination. Each slide was scored by 3 independent blinded readers on a score of 0 (no 
demyelination) to 3 (complete demyelination). All scores are restricted to the midline corpus 
callosum (boxed area). b. Nlrp3
-/-
 mice (open circles) show delayed demyelination as 
compared to WT controls (filled circles). Demyelination was quantitated by Luxol fast blue 
(LFB)/ periodic acid schiff’s (PAS) staining. Each circle represents the averaged observed 
LFB score from three readers for one mouse. The mean value of each data set is depicted by 
a red line. c. Mature myelinating oligodendrocytes in the corpus callosum were increased 
during cuprizone treatment of WT and Nlrp3
-/-
 mice as identified with GSTʌ staining (red). 
DAPI was used to label nuclei (blue). Inset shows isotype control. d. Nlrp3
-/-
 mice (white 
bar) show a significant delay in the loss of mature oligodendrocytes as compared to WT 
controls (black bars) (P=0.004 at 3 Wks, P=0.02 at 3.5 Wks and P=0.002 at 4 Wks). Mature 
oligodendrocyte depletion was quantitated by counting GSTʌ+ cells that co-localized with a 
DAPI positive nucleus. Each image was scored twice in a blind manner. Average counts with 
standard error are depicted here. e. CNPase staining of paraffin-embedded 5µm brain 
sections from Nlrp3
-/-
 and WT control mice during demyelination shows delayed loss of 
myelin in the corpus callosum of Nlrp3
-/-
 mice. Representative images for 9 - 14 mice per 
time point are shown. In d, *P< 0.05, ***P<0.005; error bars, s.e.m.  
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Figure 2.3- IL-1ȕ is not required in demyelination, astrogliosis, microglial infiltration 
and mature oligodendrocyte depletion. a. IL-1ȕ-/- mice exhibit no difference in 
demyelination. Each circle represents the averaged observed LFB score from three readers 
for one mouse. Demyelination was quantitated by Luxol fast blue (LFB)/ periodic acid 
schiff’s (PAS) staining. IL-1ȕ-/- mice (open circles) show no difference in demyelination as 
compared to WT controls (filled circles).  b. IL-1ȕ-/- mice (white bars) exhibit no difference 
in mature oligodendrocyte number as compared to age-matched WT controls (black bars) 
(P=0.29 at 3 Wks, and P=0.16 at 4 Wks).  Mature oligodendrocytes were measured by the 
GSTʌ+ stain at the corpus callosum. c. IL-1ȕ-/- mice (white bars) exhibit no difference in 
microglial infiltration as compared to age-matched WT controls (black bars) (P=0.56 at 3 
Wks, and P=0.15 at 4 Wks). Microglia were measured by RCA
+
staining at the corpus 
callosum after 3 and 4 wks of cuprizone treatment. d. IL-1ȕ-/- mice (white bars) exhibit no 
difference in astrogliosis when compared to age-matched WT controls (black bars) (P=0.80
at 3 Wks, and P=0.26 at 4 Wks).  Astrocytes were measured by the GFAP
+
stain at the corpus 
callosum after 3 and 4Wks of cuprizone treatment. GFAP was used to detect astrocyte 
accumulation in the corpus callosum. RCA
+
 or GFAP
+
 cells with an observable DAPI stained 
nucleus were counted blindly twice. Cell counts for b, c and d are averages of between 6 and 
10 mice per time point. 
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Figure 2.4- Roles of caspase-1 in demyelination, mature oligodendrocyte depletion, 
microglial infiltration and astrogliosis. a. casp1
-/-
 (open circles) and age-matched WT mice 
(filled circles) exhibit a difference in the extent of demyelination.  b. casp1
-/-
 mice (white 
bars) and age-matched WT controls (black bars) exhibit a difference in mature 
oligodendrocyte number (P=0.001 at 3 Wks, P=0.45 at 4 Wks and P=0.39 at 5 Wks).  c. 
casp1
-/-
 mice (white bars) exhibit reduced microglial infiltration at the corpus callosum when 
compared to age-matched WT controls (black bars) (P=0.008 at 3 Wks, P=0.05 at 4 Wks and 
P=0.19 at 5 Wks).  d. casp1
-/-
 mice (white bars) exhibit reduced astrogliosis at the corpus 
callosum when compared to age-matched WT controls (black bars) (P=0.02 at 3 Wks, 
P=0.01 at 4 Wks and P=0.37 at 5 Wks).  Demyelination was quantitated by Luxol fast blue 
(LFB)/ periodic acid schiff’s (PAS) staining, mature oligodendrocyte by GSTʌ, microglia by 
RCA and astrocytes by GFAP staining as described in Fig. 3. *P< 0.05, **P<0.01,
***P<0.005; error bars, s.e.m. Cell counts for b-d are averages of between 6 and 12 mice per 
time point. 
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Figure 2.5- Roles of IL-18 in demyelination, mature oligodendrocyte depletion, 
microglial infiltration and astrogliosis. a. IL-18
-/-
 mice (white bars) exhibit reduced 
microglial infiltration at the corpus callosum when compared to age-matched WT controls 
(black bars) (P=0.008 at 3 Wks).  b. IL-18
-/-
 mice (white bars) exhibit reduced astrogliosis at 
the corpus callosum when compared to age-matched WT controls (black bars) (P=0.02 at 3 
Wks). c. IL-18
-/-
 mice (white bars) and age-matched WT controls (black bars) exhibit a 
difference in mature oligodendrocyte number (P=0.001 at 3 Wks).  d. IL-18
-/-
 (open circles) 
and age-matched WT mice (filled circles) exhibit a difference in the extent of demyelination. 
Demyelination was quantitated by Luxol fast blue (LFB)/ periodic acid schiff’s (PAS) 
staining, mature oligodendrocyte by GSTʌ, microglia by RCA and astrocytes by GFAP 
staining as described in Fig. 3. *P< 0.05, **P<0.01, ***P<0.005; error bars, s.e.m. Cell 
counts for b-d are averages of between 6 and 8 mice per time point. 
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Figure 2.6- Roles of P2X7R in demyelination, mature oligodendrocyte depletion, 
microglial infiltration and astrogliosis.  a. P2X7R
-/-
 (open circles) and WT mice (filled 
circles) show no difference in demyelination during the course of cuprizone treatment. b. 
P2X7R
-/-
 (white bars) and WT (black bars) mice show no difference in mature 
oligodendrocyte depletion during cuprizone treatment (P=0.43 at 3.5Wk, P=0.93 at 4Wk, 
P=0.45 at 5Wk). c. P2X7R
-/-
 (white bars) mice show reduced microglial infiltration when 
compared to WT mice (black bars) (P=0.005 at 4Wk). d. P2X7R
-/-
 mice (white bars) show
reduced astrogliosis when compared to WT mice (black bars).  LFB/PAS (panel a), GSTʌ
(panel b), RCA (panel c) and GFAP (panel d) were used to detect myelination, mature 
oligodendrocyte, microglia and astrocytes in the corpus callosum, respectively as described 
in Fig. 3. *P< 0.05, **P<0.01, ***P<0.005; error bars, s.e.m. Cell counts for b-d are 
averages of between 4 and 8 mice per time point.
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Figure 2.7- Schematic for experimental design of phagocytosis assays and myelin 
extraction from mouse brain a. Ex vivo phagocytosis assay experimental design. Bone
marrow derived Macrophages were activated by overnight incubation with LPS. These 
macrophages were then incubated with fluorescent beads, E.coli or myelin.  Fluorescent 
bead, GFP-E.coli, and DiI -labeled myelin ingestion was quantitated by FACS and visualized 
by confocal microscopy. Culture supernatants were used for ELISA. b. Schematic for 
myelin extraction from adult mouse brain. Adult C57Bl/6 mouse brain was homogenized in 
0.32M sucrose. This homogenate was loaded in the middle of a discontinuous sucrose 
density gradient and separated by ultracentrifugation at 80,000g. The resulting crude myelin 
fraction was homogenized in cold water to release any axoplasmic content. A final 
centrifugation step resulted in isolation of myelin as a pellet that was resuspended in PBS and 
labeled with the lipophilic dye DiI.
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Figure 2.8- Nlrp3
-/-
and casp1
-/-
macrophages show enhanced myelin phagocytosis. a.
Macrophages readily phagocytose beads, E.coli, and myelin.  Fluorescent latex bead, GFP-
E.coli, and DiI -labeled myelin ingestion was visualized by confocal microscopy.  
Macrophages were stained with RCA lectin (green in all panels except in E.coli where RCA 
is red). Myelin (red), bead (blue) and E.coli (green) phagocytosis is blocked by cytD in the 
medium, compatible with the process of phagocytosis. b. Nlrp3
-/-
, casp1
-/-
 and WT 
macrophages exhibit no difference in the phagocytosis of fluorescent latex beads. Primary 
BMDM were incubated with fluorescent-labeled latex beads for 0, 30, 60 and 120 min. The 
Mean fluorescent intensity (MFI) of latex beads was measured by flow cytometry. c.
Phagocytosis of GFP-E.coli by Nlrp3
-/-
 , casp1
-/-
and WT BMDMs is not different. BMDM
were analyzed by flow cytometry as described in panel b, except cells were incubated with E.
coli expressing GFP.  d. Phagocytosis of fluorescently-labeled myelin is enhanced in Nlrp3
-/-
and casp1
-/-
 BMDM when compared to WT BMDMs. BMDM were isolated and analyzed by 
flow cytometry as described in panel b, except cells were incubated with DiI-labeled myelin.
Mean fluorescent intensity (MFI) of DiI-Myelin was measured by flow cytometry. 
Representative graphs based on 3 experiments each for E.coli and beads, and 5 experiments 
for myelin are shown here.  
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Figure 2.9- Hypothetical model for the role of the Nlrp3 inflammasome in myelin 
phagocytosis.   Myelin is phagocytosed by macrophages by multiple surface receptors 
including the complement receptor (CR-3), Scavenger receptors (SR-A I/II) and the Fc 
gamma receptor (FcȖR). Once internalized via the phagosome, lysosomal enzymes degrade 
the myelin in the phagolysosme. By an unknown mechanism myelin phagocytosis activates 
the cytosolic Nlrp3 which inhibits myelin phagocytosis thus exacerbating inflammation 
(microglial recruitment and astrogliosis) and delaying recruitment of ODG progenitor cells.  
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Figure 2.10- No difference in weight of Nlrp3
-/-
and control WT mice during cuprizone 
induced demyelination. 8-10 weeks old, male, Nlrp3
-/-
and control WT mice were fed 0.2% 
cuprizone mixed into ground chow ad libidum for 6 weeks to induce progressive 
demyelination. Untreated control mice were maintained on a diet of normal pellet chow. 
Nlrp3
-/-
and control WT mice showed no difference in weight during cuprizone treatment.
Weights (in grams on y axis) are averages of at least 9 and up to 14 mice per time point. 
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Figure 2.11 -Quantitation of macrophage staining with CD11b-APC and CD45-perCP 
antibodies and myelin phagocytosis by flow cytometry. a. Macrophages stained with 
CD11b-APC show significantly higher fluorescent staining intensity compared to staining 
with isotype control antibody conjugated with APC. b. Macrophages stained with CD45-
perCP show significantly higher fluorescent staining intensity compared to staining with 
isotype control antibody conjugated with perCP. c. Treatment with cytochalasin D inhibited 
myelin phagocytosis by macrophages leading to significantly decreased fluorescent intensity 
compared to macrophages that phagocytosed myelin in the absence of cytochalasin D.  
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Figure 2.13 Remyelination in Nlrp3
-/-
 mice remains unchanged 
a. Nlrp3
-/-
 (open circles) and age-matched WT mice (filled circles) exhibit no difference in 
the extent of remyelination at the 8, 10 and 12 week time points.  b. Nlrp3
-/-
 (white bars) and 
age-matched WT mice (filled bars) exhibit no difference in the extent of remyelination at the 
8 and 10 week time points.  c.TEM analysis in Nlrp3
-/-
 mice during remyelination indicates 
that remyelination remains unchanged relative to C57Bl/6 controls at the 10 week time point 
of remyelination. Remyelination was quantitated by Luxol fast blue (LFB)/ periodic acid 
schiff’s (PAS) staining and mature oligodendrocyte by GSTʌ as described earlier.
CHAPTER III 
A NOVEL ROLE FOR NLRC4 IN THE REGULATION OF INFLAMMATION, 
DEMYELINATION AND MYELIN DEBRIS CLEARANCE IN THE CNS  
Parts of this chapter have been adapted from Sushmita Jha, Leslie Freeman, Siddharth Y. 
Srivastava and Jenny P.-Y. Ting, A novel role for the NLR family member NLRC4 in 
regulation of neuroinflammation and demyelination, Glia, 2009, Manuscript in preparation. 
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3.1 ABSTRACT 
As a continuation of our studies to identify NLR family members involved in 
neuroinflammation we chose to analyze mice with a genetic deletion of Nlrc4 (Nlrc4
-/-
). The 
NLRC4 protein has a well documented role as a cytosolic sensor of flagellin, flagellated and 
some non-flagellated pathogens however, it’s role in inflammation remains unknown.  
NLRC4 can associate with procaspase-1 and cause its autocatalytic cleavage to active 
caspase-1. Caspase-1 in turn can cause cleavage induced maturation of over seventy 
substrates including the proinflammatory cytokines IL-1ȕ and IL-18. 
In this study we demonstrate a previously unknown role of NLRC4 in inflammation, 
demyelination and myelin debris clearance in a mouse model of cuprizone-induced 
demyelination. Nlrc4
-/-
mice showed delayed astrogliosis, microglial infiltration, mature 
oligodendrocyte death and demyelination during cuprizone treatment. These results along 
with our previous study that showed a role for NLRP3 and caspase-1 in demyelination, 
neuroinflammation and myelin debris clearance raises the possibility for the existence of 
multiple pathways upstream of caspase-1 activation in the CNS.  
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3.2 INTRODUCTION 
Neuroinflammation is a component of several diseases including, multiple sclerosis, 
Parkinson’s disease and Alzheimer’s disease.  NLR family, Caspase Recruitment domain 
containing 4 (NLRC4, also IPAF, CLAN, CARD12) protein is a cytosolic sensor of flagellin, 
flagellated pathogens such as Salmonella typhimurium (4, 5, 26),and Legionella pneumophila
(3) and non-flagellated pathogens such as Shigella flexneri (7) and Pseudomonas aeruginosa
(32). NLRC4 forms a homo-oligomeric inflammasome with caspase-1 (26). Initial 
characterization of NLRC4 in human tissues and cell lines demonstrated its direct association 
with the CARD domain of procaspase-1 through CARD-CARD interactions (40, 41). This 
interaction can cause autocatalytic processing of procaspase-1 to caspase-1 (40). A 
constitutively active NLRC4 could cause autocatalytic processing of procaspase-1 leading to 
caspase-1 dependent apoptosis in transfected cells (40). In macrophages, caspase-1 activation 
and IL-1ȕ release by cytoplasmic flagellin requires NLRC4 (4, 5, 26).   
The role of NLRC4 in inflammation remains unknown. In this study we utilized the 
cuprizone-induced mouse model of demyelination to evaluate the role of NLRC4 in 
neuroinflammation.  The cuprizone model is an ideal model to study the role of the innate 
immune system of the CNS in neuroinflammation and demyelination. It exhibits type III and 
IV MS neuropathology characterized by microglial infiltration and astrogliosis in the absence 
of T cell infiltrates (147). Demyelination and neuroinflammation are easily induced by 
administering cuprizone through the chow. The disease follows a predictable time course 
along with a reproducible pathology involving major nerve tracts such as the corpus callosum 
and cerebellar peduncles (156). This model also allows for the study of factors that affect 
inflammation in the CNS that accompany demyelination.  Using the cuprizone model, we 
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studied mice deficient in the gene encoding NLRC4 (Nlrc4
-/-
), as a way to examine the role 
of the NLRC4 in neuroinflammation and demyelination in vivo. We found a significant role 
for the NLRC4 inflammasome pathway in the activation of neuroinflammation, but we also 
found an additional function for this gene in the clearance of myelin debris.    
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3.3 MATERIALS AND METHODS 
Mice.
Nlrc4
-/-
mice were provided by Dr Vishwa Dixit (Genentech), which were further 
backcrossed to C57BL/6 mice for over nine generations. C57BL/6 mice were purchased from 
the National Cancer Institute (Bethesda, MD) and Jackson Research Labs (Bar Harbor, ME). 
All mice were 8-10 weeks old prior to the start of treatment. All animal procedures 
conducted were approved by the Institutional Animal Care and Use Committee of UNC at 
Chapel Hill.   
Cuprizone treatment. 
 8-10 weeks old male mice were fed 0.2% cuprizone [oxalic bis (cyclohexylidenehydrazide)]
(Aldrich, St. Louis, MI) mixed into ground chow ad libidum for 6 weeks to induce 
progressive demyelination. Untreated control mice were maintained on a diet of normal 
pellet chow. During cuprizone treatment mice showed lethargic movement, weight loss (Fig. 
3.7), ruffled hair and altered gait as described earlier (158, 159). 
Tissue preparation.
Mice were deeply anesthetized and intra-cardially perfused with phosphate-buffered saline 
(PBS) followed by 4% paraformaldehyde (PFA). Brains were removed, post-fixed in PFA, 
and embedded in paraffin. 5-µm coronal sections were cut at the fornix region of the corpus 
callosum. 5µm coronal sections were cut at the fornix region of the corpus callosum for 
immunohistochemistry (IHC). All analyses were restricted to the mid-line corpus callosum as 
described previously (158, 180, 181).
Staining.
86

To examine demyelination, paraffin sections were rehydrated through a graded series of 
alcohol washes and stained with Luxol fast blue-periodic acid-Schiff’s base (LFB-PAS; 
Sigma, St. Louis, MI) as described previously(158, 180, 181). Sections were read by three 
double-blinded readers and graded on a scale from 0 (complete myelination) to 3 (complete 
demyelination). Higher scores indicate greater pathology. For the detection of 
microglia/macrophages, tissue sections were rehydrated and permeabilized with 0.1% 
Triton/PBS for 20 min at room temperature and then incubated with Ricinus communis
agglutinin-1 (RCA-1) lectin (1:500, Vector) at 37 °C for 1hr. Only RCA-1
+
 cells with 
observable 4', 6’-diamidino-2-phenylindole (DAPI) stained nucleus were included in the 
quantification.  
Immunohistochemistry(IHC). 
IHC was performed on 5-µm paraffin embedded sections that were deparaffinized and 
rehydrated through alcohols as described earlier. For the detection of mature 
oligodendrocytes, the sections were processed by boiling in antigen unmasking solution 
(1:100, Vector) for 13 min in a microwave. These sections were permeabilized with 0.1% 
Triton/PBS for 20 min and incubated with 2% normal goat serum in 0.1% triton-PBS for 20 
min at room temperature. Subsequently, the sections were incubated with rabbit anti mouse 
polyclonal antibody anti- GSTʌ (1:500, Stressgen) at 4°C overnight. Sections were then 
washed in PBS and incubated with the appropriate biotinylated antibody against primary 
antibody (1:100, Vector) and texas red-conjugated avidin (1:500, Vector). The sections were 
washed and incubated with Alexa Fluor conjugated 594.  To detect astrocytes, sections were 
incubated with 5% normal goat serum in 0.1% triton-PBS for 20 min at room temperature. 
Subsequently, the sections were washed and incubated with rabbit anti-cow monoclonal 
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antibody (1:100, DAKO) and goat-anti-rabbit-fluorescein conjugated secondary antibody 
(1:100, Vector).   Immunopositive cells with an observable DAPI stained nucleus were 
counted blindly twice. Cell counts are averages of at least 9 and up to 14 mice per time point.  
Imaging.
All cell counts are within the mid line of the corpus callosum, confined to an area of 0.033 
mm
2
. An Olympus BX-40 microscope with camera (optronics engineering) and Scion image 
acquisition software was used for taking images.   
Reverse transcription-PCR and quantitative real-time reverse transcription-PCR.
Total RNA was isolated from a dissected region of the brain containing the corpus callosum 
of wild-type and Nlrc4
-/-
mice at several points during and after cuprizone treatment. RNA
isolation was performed using Trizol reagent (Ambion) under RNase-free conditions. The 
primers used were Nlrc4 forward, AATTCAGATGGGCAGACAGG, Nlrc4 reverse, 
GAGCCCTATTGTCACCAGGA, GAPDH forward, CTTCACCACCATGGAGAAGGC, 
GAPDH reverse, GGCATGGACTGTGGTCATGAG.  
Primary cell culture.
Bone marrow derived macrophages were extracted from femurs of WT, Nlrc4
-/-
, casp1
-/-
and
Nlrp3
-/-
mice.  Cells were cultured as described previously (182).  
Phagocytosis Assays.
For myelin phagocytosis experiments, myelin was extracted from adult C57BL/6 
mouse brains as described previously (207). Myelin was labeled with the lipophilic dye 1, 1’-
dioctadecyl-3, 3, 3’, 3’-tetramethylindocarbocyanine perchlorate (DiI; Molecular probes: 
SKU# D-282) as described previously (208). 0.25× 10
6
 cells/well in 24-well culture dish was 
incubated with 20µg labeled myelin for 0, 30, 60 and 120 minutes at 37°C. After 
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phagocytosis non- ingested myelin was removed by washing the cells twice with media and 
once with PBS. The internalization of myelin was quantified by measuring the mean cellular 
fluorescent intensity by flow cytometry. A Beckman coulter (Dako) CyAn ADP flow 
cytometer was used for all the above mentioned experiments. Experiments were repeated at 
least four times and the significance was determined by using student’s t-test. Differences 
were considered statistically significant if p < 0.05.
Confocal microscopy was used to visualize myelin phagocytosis by macrophages. For 
this, 0.25×10
6
 cells were plated on 24 well glass bottom plates and after 2 hours of 
phagocytosis, the cells were washed thrice with PBS and fixed with 2% paraformaldehyde 
for 10 minutes. Subsequently, cells in the wells were stained with RCA as described in the 
staining section.  A Zeiss LSM5 Pascal confocal laser scanning microscope was used for all 
the confocal microscopy. 
Statistical Analysis.
Data are expressed as mean ±s.e.m. Unpaired Student's t tests were used to 
statistically evaluate significant differences. Differences were considered statistically 
significant if p < 0.05.
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3.4 RESULTS 
NLRC4 expression is increased in the cuprizone model of demyelination 
Nlrc4 mRNA was examined by reverse transcriptase PCR (Fig 3.1b). Previous reports 
have shown that NLRC4 protein is highly expressed in mouse brain (40). The CNS of 4 week 
cuprizone treated C57BL/6 mice and Nlrc4
-/-
mice was examined for NLRC4 expression by 
IHC using an antibody against mouse NLRC4. NLRC4 expression was detected after 4 
weeks of cuprizone induced demyelination in WT C57BL/6 but not in Nlrc4
-/-
mice (Fig. 
3.1a). This time point coincides with peak inflammatory cell infiltration, demyelination and 
mature ODG death.   
Recruitment of microglia is delayed in Nlrc4
-/-
 mice 
To explore if NLRC4 has a role during cuprizone-induced neuroinflammation, we 
examined microglial accumulation in mice lacking NLRC4 (Nlrc4
-/-
) (Fig. 3.2a-b). Microglia 
are resident immune cells of the CNS that can phagocytose myelin debris, present antigens to 
T cells, and release cytokines and chemokines. The microglia populations at the corpus 
callosum were studied by Ricinus communis agglutinin-1 (RCA-1) lectin staining (Fig. 3.2a). 
Age-matched untreated (0 Wk) Nlrc4 
-/-
mice and C57BL/6 WT controls showed no 
difference in numbers of microglia at the corpus callosum (Fig 3.2b). At 3 and 4 weeks of 
cuprizone treatment there was progressive and significant reduction in microglial infiltration 
in Nlrc4
-/-
mice relative to WT controls (Fig. 3.2b, P=0.03 at 3 Wks and P=0.002 at 4 Wks). 
After 5 weeks of cuprizone treatment there was no difference in microglial accumulation 
between Nlrc4
-/-
and C57BL/6 controls (Fig.3.2b). This is consistent with other studies of the 
cuprizone model wherein the removal of an inflammatory gene did not affect pathology past 
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this time point (158, 180, 181).  These results indicate that NLRC4 contributes to microglia 
accumulation at the corpus callosum during demyelination . 
Astrogliosis is delayed in Nlrc4
-/-
 mice 
Astrocytes are the other cell population that contributes to cuprizone-induced 
neuroinflammation. We examined astrogliosis in mice lacking NLRC4 (Nlrc4
-/-
) (Fig. 3.3 a-
b). Activated astrocytes perform several overlapping roles with microglia with respect to 
neuroinflammation. The astrocyte populations at the corpus callosum was studied by glial 
fibrillary acidic protein (GFAP) staining (Fig. 3.3 a). Age-matched untreated (0 Wk) Nlrc4 
-/-
mice and C57BL/6 WT controls showed no difference in numbers of astrocytes at the corpus 
callosum (Fig 3.3b). At 3 and 4 weeks of cuprizone treatment there was progressive and 
significant reduction in astrogliosis in the Nlrc4
-/-
 mice at week 3 and 4, (Fig. 3.3b, P=0.002
at 3 Wks and P=0.009 at 4 Wks). After 5 weeks of cuprizone treatment there was no 
difference in astrogliosis between Nlrc4
-/-
and C57BL/6 controls (Fig. 3.3b). These results 
indicate that NLRC4 contributes to astrogliosis in the CNS during demyelination. 
Demyelination is delayed in cuprizone-treated Nlrc4
-/-
 mice  
Another component of the cuprizone model that is relevant to human disease is the 
demyelination process. To assess if NLRC4 plays a role in demyelination and the loss of 
mature oligodendrocytes (ODG), Nlrc4
-/-
 mice along with age matched C57BL/6 control 
(WT) mice were treated with cuprizone for 3, 4 and 5 weeks. Representative scoring of the 
extent of demyelination as measured by Luxol fast blue-periodic acid Schiff (LFB-PAS) 
staining is shown in Fig. 3.5a. Slides were read by three blinded readers on a scale of 0 (no 
demyelination) to 3 (complete demyelination). WT mice showed significant demyelination 
initiating at the 3 week time point and continuing to the end of the study at the 5 week time 
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point (Fig 3.5b). Nlrc4
-/-
mice showed a significant delay in demyelination at the 3 week 
time point when compared to WT controls (Fig 3.5b). LFB is a screening assay for myelin 
which requires further verification with more specific stains such as glutathione S transferase 
pi subunit (GSTʌ), a marker of mature ODG population. Prior to cuprizone treatment (0 Wk)
Nlrc4
-/-
mice and C57BL/6 controls showed no difference in mature ODG populations at the 
corpus callosum as shown in Fig. 3.4b. At 4 weeks of cuprizone treatment, the depletion of 
mature ODGs was attenuated in Nlrc4
-/-
mice relative to C57BL/6 controls. A quantitation of 
the composite data is shown in Fig. 3.4 b (P=0.019 at 4 Wks). After 5 weeks of cuprizone 
treatment, there was no difference in demyelination and mature ODG death between Nlrc4
-/-
and C57BL/6 control mice (Fig. 3.4b) indicating that NLRC4 delayed demyelination but did 
not obviate this process.  This is consistent with studies of other inflammatory genes in the 
cuprizone model (180, 181, 209).
Myelin phagocytosis is enhanced in Nlrc4
-/-
 macrophages
Our data thus far suggests that NLRC4 exacerbates neuroinflammation as measured 
by microglial accumulation and astrogliosis and also affects demyelination and mature ODG 
depletion.  As described previously microglia/macrophages and astrocytes actively sample 
their environment. Microglia sense their environments via surface receptors and intracellular 
sensors such as TLRs and NLRs respectively (183). One of the several roles performed by 
microglia is clearance of cellular debris including but not restricted to myelin. Removal of 
myelin debris is critical for resolution of inflammation, prevention of further death of ODGs 
and recruitment of ODG progenitors for remyelination.  To investigate the role of NLRC4 in 
myelin phagocytosis we isolated macrophages from WT and Nlrc4
-/-
mice along with Nlrp3
-/-
and casp1
-/-
 mice as positive controls for enhanced myelin phagocytosis.  Nlrc4
-/-
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macrophages showed significantly increased phagocytosis of myelin as compared to WT 
controls and similar levels as compared to Nlrp3
-/-
and casp1
-/-
 macrophages (Fig. 3.6b).
Myelin phagocytosis was studied by incubating macrophages with myelin that was labeled 
with the fluorescent carbocyanine, lipophilic dye, 1, 1’-dioctadecyl-3, 3, 3’, 3’-
tetramethylindocarbocyanine perchlorate (DiI) for 120 minutes. Myelin internalization was 
measured over time by flow cytometry. Myelin internalization was also visualized by 
confocal microscopy. 0.25 X10
6
 macrophages were plated in glass bottom 24 well plates 
(Fig. 3.6a, panel i). Internalization was detectable at 120 minutes (Fig. 3.6a, panel ii). 
Treatment with cytochalasin D, a known inhibitor of phagocytosis, was used as a negative 
control (Fig. 3.6a, panel iii). These findings suggest that NLRC4 might negatively affect 
myelin phagocytosis which is important for myelin clearance.   
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3.5 DISCUSSION 
NLRC4 protein is abundant in the adult mouse brain (40) and can associate with 
procaspase-1 to form the NLRC4 inflammasome. Caspase-1 has been shown to be important 
for the processing of over 70 substrates including the cytokines IL-1ȕ and IL-18(18, 19). 
Several studies have demonstrated the role of caspase-1 and its target proteins IL-1ȕ and IL-
18 in neuroinflammation however, the role of NLRC4 or its endogenous triggers in the CNS 
remain undescribed. Our studies with NLRP3 deficient (Nlrp3
-/-
) mice in the cuprizone 
model showed a NLRP3/caspase-1/IL-18-dependent but IL-1ȕ independent mechanism 
which leads to demyelination and the loss of mature oligodendrocytes. Moreover, our results 
in Nlrp3
-/-
 mice showed that NLRP3 deficiency delayed but did not obviate demyelination 
and neuroinflammation. These results raised the possibility of the involvement of other NLR 
proteins possibly capable of processing caspase-1 in neuroinflammation and demyelination.   
Here, we provide evidence that Nlrc4
-/-
mice exhibit delayed demyelination and 
neuroinflammation in the cuprizone induced mouse model of demyelination. Moreover 
stimulated by our earlier finding that Nlrp3
-/-
 and casp1
-/-
macrophages show an increased 
ability to phagocytose myelin debris we investigated myelin phagocytosis in macrophages 
from Nlrc4
-/-
mice. Bone marrow derived macrophages from Nlrc4
-/-
mice have increased 
capacity for myelin phagocytosis as compared to WT macrophages, this enhanced 
phagocytosis was similar to that observed with Nlrp3
-/-
and casp1
-/-
 macrophages.  
Myelin phagocytosis is an important component of MS pathology.  Macrophage and 
microglial clearance of myelin debris is critical to repair mechanisms following 
demyelination in both central and peripheral nervous system diseases (136, 138, 177, 203, 
204). Myelin debris has dual proinflammatory and anti-regenerative functions, firstly, myelin 
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debris can activate the complement system to form membrane attack complexes that 
disintegrate intact myelin (139) and secondly, myelin debris inhibits oligodendrocyte 
precursor cell differentiation in the adult rat CNS thus impairing remyelination (135). 
Therefore, myelin debris removal is critical for both resolution of demyelination and for 
creating an environment conducive for remyelination. This corroborates our in vivo data that 
showed delayed demyelination in Nlrc4
-/-
mice.   
It remains unclear how NLRC4 exerts its effects on phagocytosis. Myelin consists of 
protein and lipid components. One possible mechanism for the involvement of NLRC4 in 
myelin phagocytosis is the known structural homology between myelin basic protein (MBP) 
and flagellin (210). The structural homology between the flagellin of Borrelia burgdorferi
and myelin basic protein led to the “mistaken-self” hypothesis for the autoimmune attack 
against myelin leading to demyelination observed during neuroborreliosis. Myelin differs in 
composition from other plasma membranes in its unusually high lipid content. Lipids 
constitute 70-75% dry weight of myelin (211). The molar ratio of lipids is 2:2:1:1 for 
cholesterol/ phospholipid/ galactolipid/ plasmalogen. Another possible mechanism could be 
that after phagocytosis phospholipids in myelin are degraded by phospholipase A2 causing 
release of lysophosphatidylcholine (LPC) (212). LPC can suppress maturation and release of 
IL-1ȕ in mouse microglial cells (213).  
In addition there are several receptor complexes that are involved in myelin 
phagocytosis including scavenger receptors I and II (SR-AI/II) (143, 145), complement 
receptor 3 (CR-3), galectin-3 (144), Fc gamma receptor (FcȖR) (205), and the low-density 
lipoprotein receptor-related protein 1(LRP-1) (214).  It is possible that NLRC4 affects any, 
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some or all of these receptors by affecting their expression or signal transduction pathways 
required for myelin phagocytosis.
In summary, the dual roles of NLRC4 in exacerbating neuroinflammation and 
inhibiting myelin debris clearance indicate that inhibition of NLRC4 may prove to be a 
valuable therapeutic approach for demyelinating diseases such as MS.  These results show 
that neuroinflammation, demyelination and myelin debris clearance in this disease model are 
mediated by an NLRC4-dependent pathway.  
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Figure 3.1- Expression of NLRC4 in the CNS a. 4 week cuprizone treated WT  mice brains 
were examined for NLRC4 expression by IHC using an antibody against mouse NLRC4. 
NLRC4 expression (green) was detected after 4 weeks of cuprizone induced demyelination in 
WT but not in Nlrc4
-/-
mice (Fig. 3.1a). RCA (red) was used to detect microglia at the corpus 
callosum.  DAPI was used to label nuclei (blue). b. RT-PCR was used to detect Nlrc4 mRNA 
levels in total RNA from brains of cuprizone treated and untreated WT and Nlrc4
-/-
 mice. 
GAPDH was used as a positive control and water control was included as a negative control 
for the PCR reaction. 
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Figure 3.2- Role of NLRC4 in immune cell infiltration. a. Nlrc4
-/-
 mice (open circles) 
show reduced cellularity as compared to WT controls (filled circles). Cellularity was 
quantitated by periodic acid schiff’s (PAS) staining. Each circle represents the averaged 
observed PAS score from three readers for one mouse. The mean value of each data set is 
depicted by a red line.  b. Nlrc4
-/-
 mice exhibit reduced microglial accumulation as compared 
to age-matched WT controls. Microglial cells were measured by RCA
+
staining at the corpus 
callosum after 3 and 4Wks of cuprizone treatment. RCA (red) was used to detect microglial 
accumulation in the corpus callosum.  DAPI was used to label nuclei (blue). c. Quantitation
of microglial accumulation showed reduced microglia  at the midline corpus callosum in 
Nlrc4
-/-
 mice (open bars) after 3 and 4 weeks of cuprizone treatment (P=0.03 at 3 Wks and 
P=0.002 at 4 Wks).  *P< 0.05, **P<0.01, ***P<0.005; error bars, s.e.m. Cell counts are 
averages of between 4 and 11 mice per time point.
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Figure 3.3- Role of NLRC4 in astrogliosis. Nlrc4
-/-
 mice exhibit reduced astrogliosis when 
compared to age-matched WT controls as measured by GFAP
+
cell population at the corpus 
callosum after 3 and 4Wks of cuprizone treatment. a. GFAP (green) was used to detect 
astrocyte accumulation in the corpus callosum.  DAPI was used to label nuclei (blue). b.
Quantitation of astrogliosis showed significantly reduced astrocytes at the midline corpus 
callosum in Nlrc4
-/-
 mice (open bars) after 3 and 4 weeks of cuprizone treatment (P=0.002 at 
3 Wks and P=0.009 at 4 Wks). *P< 0.05, **P<0.01, ***P<0.005; error bars, s.e.m. Cell 
counts are averages of between 4 and 11 mice per time point.
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Figure 3.4- Role of NLRC4 in mature ODG depletion. Nlrc4
-/-
 mice show a significant 
decrease in oligodendrocyte death during demyelination. a. GSTʌ (red) was used as a marker 
to detect mature myelinating oligodendrocyte accumulation. DAPI was used to label nuclei 
(blue). b. Quantitation of GSTʌ+ cells showed significantly more  oligodendrocytes at the 
midline corpus callosum in Nlrc4
-/-
 mice (open bars) after 4 weeks of cuprizone treatment 
(P=0.019 at 4 Wks). *P< 0.05, **P<0.01, ***P<0.005; error bars, s.e.m. Cell counts are 
averages of between 4 and 11 mice per time point.
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Figure 3.5- Role of NLRC4 in demyelination. Nlrc4
-/-
 mice (open circles) show delayed 
demyelination as compared to WT controls (filled circles). Each slide was scored by 3 
independent blinded readers on a score of 0 (no demyelination) to 3 (complete 
demyelination). All scores are restricted to the midline corpus callosum (boxed area).
Demyelination was quantitated by Luxol fast blue (LFB)/ periodic acid schiff’s (PAS) 
staining. Each circle represents the averaged observed LFB score from three readers for one 
mouse. The mean value of each data set is depicted by a red line. 
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Figure 3.6- Role of NLRC4 in myelin phagocytosis. a. Macrophages readily phagocytose 
DiI-labeled myelin. 0.25 X10
6
 macrophages were plated in 24 well plates. These 
macrophages were incubated with DiI-labeled myelin (red) for 2 hours.  Myelin phagocytosis 
was visualized by confocal microscopy (panel ii). As negative control samples were treated 
with cytochalasin D a known inhibitor of phagocytosis, in the medium (panel iii). 
Cytochalasin D blocked myelin phagocytosis.  b. Phagocytosis of fluorescently-labeled 
myelin was enhanced in Nlrc4
-/-
macrophages when compared to WT macrophages. 
Macrophages were isolated and analyzed by flow cytometry as described previously in the 
methods section. Mean fluorescent intensity (MFI) of DiI-Myelin was measured by flow 
cytometry. Nlrp3
-/-
and casp1
-/-
 BMDMs were used as positive controls of myelin 
phagocytosis. Data from 4 experiments are shown here.  
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Figure 3.7 Weight of Nlrc4
-/-
and control WT mice was similar during cuprizone 
induced demyelination. 8-10 weeks old, male, Nlrc4
-/-
and control WT mice were fed 0.2% 
cuprizone mixed into ground chow ad libidum for 5 weeks to induce progressive 
demyelination. Untreated control mice were maintained on a diet of normal pellet chow. 
Nlrc4
-/-
and control WT mice showed no difference in weight during cuprizone treatment.
Weights (in grams on y axis) are averages of at least 4 and up to 11 mice per time point. 
CHAPTER IV  
CONCLUSIONS AND FUTURE DIRECTIONS 
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The role of the NLR family members as sensors of PAMPs and DAMPs is a field of 
extensive study however their role in neuroinflammation and demyelination remains largely 
unexplored. As discussed in detail in chapter 1, mutations in NLRP3 in humans leads to three 
autoinflammatory syndromes - FCAS, MWS and CINCA that are collectively referred to as 
CAPS(52-56). CINCA patients often display chronic aseptic meningitis which is reversed 
after treatment with the IL-1ȕ receptor antagonist Anakinra (164). This is indicative of a role 
for NLRP3 in neuroinflammation. The aim of this dissertation was to firstly; elucidate the 
possible contribution of NLRP3 to neuroinflammation, demyelination and remyelination, 
secondly to determine the molecular mediators and mechanisms of NLRP3 dependent 
regulation of neuroinflammation and demyelination and lastly to identify other NLRs that 
could play pro- or anti-inflammatory roles in demyelination. To address these questions we 
utilized a two pronged approach utilizing an in vivo cuprizone-induced mouse model of 
neuroinflammation, demyelination and remyelination and ex vivo macrophage based assays. 
Our studies utilized an extensive panel of mice deficient in genes encoding either NLRs or 
their signaling/effector components including, Nlrp3
-/-
, casp-1
-/-
, P2X7R
-/-
, IL-1ȕ-/-, IL-18-/-
and Nlrc4
-/-
 mice. Table 4.1 summarizes the findings from these studies.  
1. Neuroinflammation, demyelination and myelin debris clearance in the cuprizone 
model is NLRP3 inflammasome dependent.   As described in detail in chapter 2 mice 
lacking Nlrp3 and caspase-1 exhibited reduced neuroinflammation, demyelination and 
mature oligodendrocyte loss in the cuprizone-induced demyelination and 
neuroinflammation model. The absence of IL-1ȕ did not affect disease outcome, while 
the absence of P2X7R reduced neuroinflammation but not demyelination.  Macrophages 
from Nlrp3
-/-
 and casp-1
-/-
 but not WT mice exhibited augmented capacity to phagocytize 
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and clear myelin debris.  This ability was specific to myelin phagocytosis and did not 
extend to phagocytosis of latex beads or bacteria.
Several new research opportunities and questions arise as a result of these studies; 
firstly what are the DAMPs that might activate the inflammasome pathways in the CNS, 
in complex immune diseases such as multiple sclerosis? Secondly, what are the surface 
receptors on microglia/macrophages and potentially astrocytes that could sense myelin 
and activate downstream signaling pathways leading to the activation of the 
inflammasome related or other NLRs?  
Is the expression of the receptors involved in myelin phagocytosis regulated 
by expression of NLRP3?
Several surface molecules are important for myelin phagocytosis, including 
complement-receptor-3 (CR-3), scavenger-receptor-AI/II (SR-AI/II) and Fc gamma receptor 
(FcȖR) (138, 143, 145, 215, 216). Recent data also implicate the Mac-3 molecule (also 
known as galectin-3) (144) and the low-density lipoprotein receptor-related protein 1(LRP-1) 
in myelin phagocytosis (214).  Downstream signaling pathways necessary for myelin 
phagocytosis include Ras, PI3K, and PLCȖ.
Our preliminary studies have shown that myelin phagocytosis by CD11b and SRAI/II 
is independent of NLRP3 expression. Suggesting that, further studies investigating the 
expression of other receptors such as Mac-3, LRP-1 and FcȖR during myelin phagocytosis in 
WT and Nlrp3
-/-
macrophages are required. Additional experiments could include blocking 
myelin phagocytosis by antibodies against these receptors to establish if one or more 
receptors are responsible for the increased myelin phagocytosis that is observed in Nlrp3
-/-
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macrophages. Anti-CR3 (216), anti-FcȖR (141), anti-SRA-I/II (143) and anti-Mac3 blocking 
antibodies (144) have been successfully used previously to reduce myelin phagocytosis.    
Does NLRP3-regulated myelin phagocytosis rely on conventional myelin 
phagocytosis signaling pathways? 
The Ras, PI3K, and PLCȖ signaling pathways have been shown to be necessary for 
myelin phagocytosis pharmacological inhibitors against specific components of these 
pathways could be used to elucidate their relative contribution to myelin phagocytosis in WT 
and Nlrp3
-/-
macrophages. The PI3K pathway inhibitors, Ly294002 and wortmannin and the 
PLCȖ ҏinhibitors, 3-nitrocoumarin (3-NC) and U-73122 have been extensively studied and 
can be used for these studies (141-144).
How does the increased myelin phagocytosis in Nlrp3
-/-
macrophages correlate 
with in vivo delay in demyelination in Nlrp3
-/-
mice?
Macrophage and microglia mediated myelin debris phagocytosis has been reported in 
multiple sclerosis plaques as well as mouse models of CNS and PNS neuroinflammatory 
disorders (217, 218). To study myelin phagocytosis in vivo Oil red O (ORO) staining is 
performed.  ORO is a lipophilic dye that stains myelin degradation products such as 
triglycerides and lipoproteins.  ORO staining and/or antibody mediated detection of MBP 
along with a microglial markers (such as RCA or CD11b) can be used to study microglial 
myelin phagocytosis. A recent study of mice deficient in the Axl gene (Axl
-/
) showed that 
cuprizone-treated Axl
-/-
 mice exhibit delayed myelin debris clearance (219).  While WT mice 
showed robust ORO staining after 4 weeks of cuprizone treatment Axl
-/-
 did not show ORO 
staining until 6 weeks. Our preliminary studies with Nlrp3
-/-
mice show strong ORO staining 
after 5 weeks of cuprizone treatment.  Since our ex vivo data utilizing mouse macrophages 
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showed increased phagocytosis in Nlrp3
-/-
 macrophages as compared to WT macrophages a 
comprehensive study utilizing ORO staining to examine myelin phagocytosis in vivo in mice 
from 2 to 5 weeks after start of cuprizone treatment will allow for a better understanding of 
the role of NLRP3 in myelin phagocytosis in vivo.
2. Remyelination in the cuprizone model is NLRP3 independent.  Regulation of 
remyelination is a potential therapeutic intervention for MS. Previous studies in the 
cuprizone model have shown that remyelination is dramatically reduced in IL-1ȕ-/- mice 
(165). IL-1ȕ regulates remyelination via its regulation of IGF-1 which is critical for 
conversion of ODG progenitors to mature ODGs (165, 188). Moreover, transgenic mice 
constitutively expressing IGF1 have reduced mature ODG death by apoptosis (166, 167). 
Thus, we hypothesized that NLRP3 via its regulation of IL-1ȕ processing and 
consequently IGF-1 may regulate oligodendrogenesis and remyelination. However our 
data with Nlrp3
-/-
 mice during remyelination (8, 10 and 12 week time points) indicated 
that remyelination remains unchanged relative to C57Bl/6 controls by GST pi and 
LFB/PAS staining, and TEM analysis. Interestingly our preliminary data with 
remyelination utilizing IL-18
-/-
 mice showed that these animals have more rapid 
remyelination as compared to WT controls at the same time point, indicating that IL-18 
may be detrimental to remyelination in vivo. These findings are novel in that they provide 
inhibition of a NLRP3 as a novel therapeutic intervention for MS. Earlier studies with 
other mediators of neuroinflammation and demyelination have been inconsequential in 
terms of clinical translation due to the dual role of these mediators in demyelination and 
remyelination. Thus, compromising their therapeutic use. Moreover, this is the first report 
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documenting the role of IL-18 during remyelination. A detailed analysis of ODG 
progenitor cell population and their proliferation as compared to WT controls during 
remyelination in the cuprizone model may yield interesting insight into the mechanistic 
role of IL-18 in remyelination. In addition a study of casp-1
-/-
 and IL-1ȕ-/-/IL-18-/- mice 
during remyelination may also provide a better understanding of the relative contribution 
of these molecules towards remyelination in this model.  To establish the role of caspase-
1 and IL-18 in ODG progenitor proliferation BrdU incorporation in NG2
+
 ODG 
progenitor cell population can be studied as described previously (158). NG2
+
 BrdU
+
cells can be detected by immunofluorescence for NG2 and quantitated. Moreover, IGF-1 
expression in casp-1
-/-
 and IL-1ȕ-/-/IL-18-/- mice versus WT control mice can be studied by 
IGF-1 ELISA.
3. Neuroinflammation, demyelination and myelin debris clearance in the cuprizone 
model is NLRC4 dependent. Considering the delay but not complete abolition of 
demyelination and neuroinflammation in the cuprizone model our final question explored 
the existence of other NLRs that could compensate for the loss of NLRP3.  Since NLRP3 
dependent caspase-1 cleavage is required for neuroinflammation and demyelination in 
our model we explored other NLR proteins that could cleave caspase-1. NLRC4 can 
associate with procaspase-1 and cause its autocatalytic cleavage to active caspase-1. 
However, NLRC4 is a cytosolic sensor for flagellin, flagellated and some non-flagellated 
pathogens so we expected that NLRC4 would not contribute to inflammation in the 
cuprizone model. Interestingly, our data with Nlrc4
-/-
mice showed delayed astrogliosis, 
microglial infiltration, mature oligodendrocyte death and demyelination. Nlrc4
-/-
mice 
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also showed a similarity to Nlrp3
-/-
mice in terms enhanced ability to clear myelin debris. 
These results raise the possibility of the existence of multiple contributing pathways 
upstream of caspase-1 activation that could lead to demyelination and 
neuroinflammation. The known structural homology between myelin basic protein 
(MBP) and flagellin or regulation of NLRC4 by myelin lipid mediators could provide a 
possible explanation. As in the case of NLRP3 regulated myelin debris clearance the 
identity of surface receptors involved in myelin phagocytosis and mechanism of delivery 
to the cytosolic NLR sensor remains unexplored. Future studies investigating the role of 
lipid and protein components of myelin such as by utilizing purified myelin basic protein 
or inhibitors of phospholipase A2 in phagocytosis experiments with macrophages from 
WT and Nlrc4
-/-
mice could provide much insight into the mechanism and mediators of 
myelin phagocytosis.
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Table 4.1. Summary of cuprizone studies 
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Figure 4.1 Summary of possible moleculat mechanisms.  Mature ODG cell death leads to release of ATP, 
myelin and other unknown DAMPs that may contribute to neuroinflammation and/or demyelination.  ATP 
signaling via P2X7R contributes to microglial accumulation. Other unknown DAMPs are sensed via the NLRP3 
inflammasome complex and lead to neuroinflammation and demyelination. Myelin phagocytosis is inhibited by 
the NLRP3 inflammasome by unknown mechanisms. 
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